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The rates of induction of labor (IOL) are rising worldwide; in 2015 
approximately every fourth labor (24.8%) in Finland was induced. The role of 
cervical ripening in success of IOL is well established. Pharmacological and 
mechanical methods, including Foley catheter (FC), are available for cervical 
ripening. The methods have comparable vaginal delivery rates, but FC is 
associated with lower risk of uterine hyperstimulation and adverse events. 
The mechanism of FC use consists of direct mechanical dilation of the cervix 
and lower uterine segment, and local secretion of endogenous 
prostaglandins. Little is known of the effect of FC on cervical biochemical 
mediators, such as insulin-like growth factor binding protein-1 (IGFBP-1) 
and its phosphorylated isoform (phIGFBP-1), matrix metalloproteinases 
(MMPs), and their tissue inhibitors (tissue inhibitors of metalloproteinase, 
TIMPs). Although risk factors for induction failure, such as unfavorable 
cervix, post-term pregnancy, and nulliparity, are recognized, prediction of 
successful IOL is difficult. The aim of this study was to evaluate FC for labor 
induction in prolonged and post-term pregnancy, in nulliparous women, in 
women with premature rupture of membranes (PROM) at term, and in 
outpatient use. The secondary aim was to investigate the effect of FC on 
cervical biomarkers, and their predictive value in indicating the success of 
IOL by FC. 
 
Our studies were conducted in the Department of Obstetrics and Gynecology 
of Helsinki University Hospital between 2011 and 2015. The randomized 
controlled trial (RCT) on labor induction after term PROM (III) was carried 
out in collaboration with Helsinki, Tampere, and Oulu University Hospitals. 
The participants were randomly allocated to IOL by FC or oral misoprostol in 
1:1 ratio. In all studies, the data on study population characteristics, 
pregnancy, and delivery outcomes were collected from the hospital records. 
The main outcome measures of studies I–IV were the rates of cesarean 
section (CS) and maternal and neonatal infections. In study V, the main 
outcome measures were the concentrations of cervical biomarkers IGFBP-1, 
phIGFBP-1, MMP-2, MMP-8, MMP-9, TIMP-1, and TIMP 2. Univariate and 
multivariate logistic regressions were used to estimate relative risks (RRs) by 
odds ratios (ORs) with 95% confidence intervals (CIs). In the study on 
cervical biomarkers, serial cervical swab samples were collected at FC 
insertion and expulsion. The concentrations of IGFBP-1, phIGFBP-1, MMP-
2, MMP-8, MMP-9, TIMP-1, and TIMP-2 were analyzed by 
immunoenzymometric assays and by commercial enzyme-linked 




The total study population consisted of 1693 women, of which 1344 (79%) 
underwent IOL by FC. The lowest rate of CS (24%) occurred in women 
undergoing IOL after term PROM, and the highest rate (44%) was observed 
in nulliparous post-term women (V). In post-term pregnancy, a sixfold risk 
(OR 6.2, 95% CI 3.2−12.1) of CS occurred in nulliparous women undergoing 
IOL compared to those with spontaneous onset of labor (37% vs. 9%; 
p<0.001). In multiparous women, the corresponding rates of CS were not 
significantly different (3% vs. 1%, p=0.2). The CS rates were significantly 
different neither between FC and misoprostol groups (24% vs. 18%; p=0.36), 
nor between outpatients and inpatients (32% vs. 32%; p=0.82). In our 
univariate analysis, the factors associated with an increased risk of CS in 
nulliparous women following IOL by FC were maternal age ≥ 37 years (OR 
1.9, 95% CI 1.0−3.6; p=0.04), obesity (OR 1.8, 95% CI 1.1−3.1; p=0.03), 
gestational diabetes (OR 1.9, 95% CI 1.2−3.1; p=0.01), and Bishop score ≤ 3 
(OR 1.6, 95% CI 1.1−2.4; p=0.02). By our multivariate analysis, need for 
oxytocin induction (OR 2.9, 95% CI 1.8−4.5), and request of early epidural 
analgesia (OR 9.9, 95% CI 2.1 – 47.5) were associated with increased risk of 
CS. 
 
The median (range) rate of maternal intrapartum infections following IOL by 
FC was 5 (2−6) % in our study, and the rate of postpartum infections was 3 
(1−4) %. The maternal intrapartum infection rates were not significantly 
different between induced and spontaneous labor (6% vs. 2%; p=0.13 in 
nulliparas, and 2% vs. 1%; p=0.54 in multiparas), between the methods of FC 
and misoprostol (2% vs. 2%; p=0.47), or between outpatients and inpatients 
(7% vs. 3%; p=0.51). Gestational diabetes was associated with an increased 
risk of intrapartum infection (OR 4.3, 95% CI 1.7−11.0; p=0.002). No 
significant risk factors were identified for postpartum infections. The median 
(range) rate of neonatal infections following FC induction was 6 (1−9) % 
(clinical sepsis 2 [1−3] % and suspected infections 4 [1−5] %). The neonatal 
infection rates were similar following FC and misoprostol (1% vs. 5%; 
p=0.22), and between outpatients and inpatients (5% vs. 5%; p=0.83). 
 
The median cervical IGFBP-1 and phIGFBP-1 concentrations increased, 
while MMP-8, MMP-9, and TIMP-2 concentrations decreased during FC 
induced cervical ripening. However, there were no significant differences in 
the biomarker concentrations in successful and failed labor inductions. 
 
In conclusion, labor induction by FC in prolonged and post-term pregnancy 
was as safe as spontaneous labor, but was associated with a high rate of CS in 
nulliparous women. Factors associated with the increased risk of CS in 
nulliparous women were advanced maternal age, obesity, gestational 
diabetes, unfavorable cervix, need for oxytocin induction, and request for 
early epidural analgesia. Since the first CS has a major impact on subsequent 
pregnancies, indications and management of labor induction in nulliparous 
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women should be carefully considered. FC and misoprostol can both be used 
for IOL in women with term PROM, with no difference in the rates of 
maternal or neonatal infections when prophylactic antibiotics are used. FC 
also appears safe and feasible for outpatient use. The concentrations of 
cervical biomarkers IGFBP-1 and phIGFBP-1 increase, whereas MMP-8, 
MMP-9, and TIMP-2 decrease during FC induced cervical ripening in 
nulliparous women. However, these cervical biomarkers appear unsuitable 





The incidence of induction of labor (IOL) is rising worldwide, with a rate of 
20−30% in developed countries at present (1-3). In Finland, almost every 
fourth pregnancy is induced (4). The increasing rates of IOL may be 
explained by increasing maternal age, obesity, and medical conditions, as 
well as improved fetal monitoring. Several clinical guidelines and 
recommendations on indications and optimal timing for IOL exist (3, 5-7). 
The most common indications for IOL are post-term pregnancy and 
premature rupture of membranes (PROM) (1, 2, 8). 
 
The exact mechanism of initiation of parturition is not completely 
understood. Cell-free fetal DNA has been suggested to trigger the 
biochemical process of cervical ripening, leading to onset of labor (9, 10). The 
role of cervical ripening in success of IOL is well established; an unripe cervix 
is associated with high risk of induction failure, failure to progress in labor, 
cesarean section (CS), infections, fetal distress, and postpartum hemorrhage 
(11-13). 
 
The pharmacological and mechanical cervical ripening methods available in 
Finland include misoprostol and Foley catheter (FC). The use of FC has been 
widely adopted in clinical practice in Finland over the past few years. The 
mechanism of FC use consists of direct mechanical stretching of the cervix 
and lower uterine segment, and stimulation of endogenous prostaglandin 
(PG) release (14, 15). The rates of vaginal delivery and infectious morbidity 
are comparable following the use of FC and PG, as demonstrated by several 
studies (16-20). FC is associated with a lower risk of uterine hyperstimulation 
and adverse events, thus appearing suitable for use in outpatients and in 
women with a history of a previous CS (21-26). Little is known about the use 
of FC in women with PROM at term. 
 
IOL has previously been considered to increase the rate of CS, but more 
recent research demonstrates that IOL is, in fact, associated with a decrease 
in CS rates compared to expectant management at or beyond term (27-31). 
Post-term pregnancy and nulliparity are significant risk factors for induction 
failure and perinatal complications (32, 33). When considering IOL, the 
indication, maternal and fetal well-being, gestational age, risk factors, and 
cervical ripeness need to be individually assessed, and the women informed 
of the risks and benefits related to IOL. 
 
A quantity of maternal, neonatal, resource, and treatment related factors 
influence the total health care costs of labor induction. However, there is 
evidence that inducing labor in women with complications is associated with 
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lower health care costs than expectant management (34, 35). Moving the 
process of cervical ripening from inpatient to outpatient setting may also 
decrease use of health care resources and costs (26, 36). Maternal 
satisfaction is associated with several health, social, and care factors (37). 
Women may be less satisfied with their care if their labor is induced (38), 
which highlights the importance of information, support, and counseling in 
care of women undergoing IOL. 
 
The present study was designed to investigate the safety and efficacy of the 
FC in labor induction. We specifically focused on IOL in late-term and post-
term pregnancies, with an interest in nulliparous women, term pregnancies 
with PROM, and outpatient labor induction. Furthermore, we examined the 
effect of FC on cervical biomarkers, and their predictive value in the success 





Synnytyksen käynnistysten määrä on kasvanut kaikissa kehittyneissä maissa, 
nykyisin noin joka neljäs synnytys käynnistetään. Suomessa synnytyksistä 
käynnistettiin 13.9 % vuonna 1993, ja 24.8 % vuonna 2015. Synnytyksen 
käynnistys aloitetaan kohdunkaulan kypsyttämisellä mekaanisesti 
pallokatetrilla, eli ns. balonkimenetelmällä, tai lääkkeellisesti 
prostaglandiinilla. Kansainvälisten julkaisujen mukaan balonkimenetelmän 
ja prostaglandiinien tehossa, keisarileikkausten määrissä tai infektioiden 
esiintymisessä ei ole todettu eroja. Balonkimenetelmässä esiintyy kuitenkin 
vähemmän haittoja, kuten kohdun hyperstimulaatiota ja sikiön 
sykemuutoksia. Balonkimenetelmässä kohdunkaulan sisäsuun ja 
lapsivesikalvojen väliin viedään katetri, jonka päässä oleva balonki täytetään 
fysiologisella suolaliuoksella. Balonki laajentaa kohdunkaulaa mekaanisesti 
ja aiheuttaa myös endogeenisten prostaglandiinien vapautumista kudoksista. 
Balonkimenetelmän vaikutusta kohdunkaulakanavan biokemiallisiin 
välittäjäaineisiin, tai niiden vaikutusta balongilla käynnistetyn synnytyksen 
kulkuun ei tunneta. 
 
Helsingin yliopistollisessa keskussairaalassa vuosien 2011 ja 2015 välillä 
toteutettu tutkimus selvittää balonkimenetelmän tehokkuutta ja 
turvallisuutta synnytyksen käynnistyksessä yliaikaisessa raskaudessa, 
ensisynnyttäjillä, lapsivedenmenon jälkeen, sekä polikliinisessa 
käynnistyksessä. Lisäksi halusimme tutkia kohdunkaulakanavassa 
tapahtuvia biokemiallisia muutoksia balonkikäynnistyksen aikana, sekä 
niiden vaikutusta synnytyksen käynnistymiseen. 
 
Tulostemme mukaan balonkikäynnistys on yliaikaisessa raskaudessa (≥ 41+5 
raskausviikolla) yhtä turvallista kuin synnytyksen spontaani käynnistyminen, 
mutta käynnistys kuitenkin lisää keisarileikkausten määrää ensisynnyttäjillä. 
Jopa yli kolmasosa ensisynnyttäjistä, joiden synnytys on käynnistetty, joutuu 
kiireelliseen keisarileikkaukseen, kun taas spontaanisti käynnistyneessä 
synnytyksessä vain joka yhdestoista synnytys päätyy keisarileikkaukseen. 
Tavallisin keisarileikkauksen syy on epäonnistunut synnytyksen käynnistys 
tai pitkittynyt synnytys. Synnyttäjän ikä ≥ 37 vuotta, ylipaino (BMI ≥ 30), 
raskausdiabetes, kohdunkaulan kypsymättömyys (Bishopin pisteet ≤ 3), 
oksitosiinin tarve supistusten aloittamiseksi ja aikainen epiduraalipuudutus 
(ennen säännöllisiä supistuksia tai kohdunsuun ollessa avautunut ≤ 3 cm) 
vaikuttivat käynnistyksen epäonnistumiseen. Äidin synnytyksenaikaisia 
infektioita esiintyi tutkimuksen aikana 5 (2−6) %, synnytyksenjälkeisiä 
infektioita 3 (1−4) % ja vastasyntyneiden infektioita 6 (1−9) % (kliinisiä 
infektioita 1.8 [1−3] % ja infektioepäilyjä 4 [1−5] %). Raskausdiabetes, 
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pitkittynyt synnytys ja aikainen epiduraalipuudutus liittyivät äidin ja 
syntyneen lapsen infektioihin. 
 
Helsingin, Tampereen ja Oulun yliopistosairaaloiden yhteisessä 
satunnaistetussa monikeskustutkimuksessa vertasimme balonkia ja 
misoprostolia synnytyksen käynnistämisessä lapsivedenmenon jälkeen. 
Totesimme molempien olevan turvallisia vaihtoehtoja, eikä 
keisarileikkausten tai infektioiden määrissä ollut eroja 
käynnistysmenetelmien välillä. Tulostemme mukaan myös polikliininen 
balonkikäynnistys, jossa kohdunkaulan kypsytys tapahtuu kotona, on 
täysiaikaisissa normaaleissa raskauksissa yhtä turvallinen kuin 
osastopotilaana toteutettava balonkikäynnistys. Synnyttäjistä 85 % oli 
tyytyväisiä polikliiniseen menetelmään, ja yli 90 % koki saamansa ohjauksen 
riittävänä ja turvallisena. 
 
Analysoimme balonkikäynnistyksen vaikutusta ensisynnyttäjien 
kohdunkaulan biokemiallisiin välittäjäaineisiin, kuten insuliininkaltaista 
kasvutekijää sitovaan proteiiniin-1 (IGFBP-1) ja sen fosfyryloituneeseen 
muotoon (phIGFBP-1), matriksin metalloproteinaaseihin (MMP) -2, -8, -9, 
sekä niitä sääteleviin estäjäproteiineihin (TIMP) -1 ja -2. Totesimme, että 
IGFBP-1- ja phIGFBP-1-pitoisuudet kohdunkaulassa lisääntyvät, ja MMP-8-, 
MMP-9- ja TIMP-2-pitoisuudet vähenivät balonkikäynnistyksen aikana. 
Näiden biomarkkereiden pitoisuuksien muutosten avulla ei kuitenkaan voitu 
ennustaa synnytyksen käynnistyksen kulkua tai synnytystapaa. 
 
Yhteenvetona voidaan todeta, että balonki on tehokas ja turvallinen 
synnytyksen käynnistysmenetelmä, joka soveltuu myös polikliiniseen 
käyttöön ja synnytyksen käynnistykseen lapsivedenmenon jälkeen. 
Tutkimuksemme mukaan synnytyksen käynnistys ensisynnyttäjän 
yliaikaisessa raskaudessa kuitenkin lisää keisarileikkauksen 
todennäköisyyttä. Tutkimamme kohdunkaulan biomarkkerit IGFBP-1, 
MMP-2, MMP-8, MMP-9, TIMP-1 ja TIMP-2 eivät vaikuta soveltuvan 













REVIEW OF THE LITERATURE 
CERVICAL RIPENING AND ONSET OF LABOR 
PHYSIOLOGY OF CERVICAL RIPENING 
 
Cervical ripening consists of a series of biochemical processes involving 
various inflammatory mediators including PGs, interleukins, insulin-like 
growth factor binding protein-1 (IGFBP-1), matrix metalloproteinases 
(MMPs), and hormonal factors such as estrogen and progesterone (39-42). 
However, the exact mechanism is not completely understood. The cervix 
contains approximately 15% smooth muscle, mostly located in the upper 
segment of the cervix (43). The underlying stroma consists of collagen 
bundles, with glycosaminoglycan and proteoglycan molecules between the 
collagen fibers (43). During cervical ripening, an increase in hyaluronic acid 
concentration, and a decrease in dermatan and chondroitin sulfate 
concentrations, occur in the cervical stroma (44). The resulting reduction in 
collagen density, remodeling of collagen fibers, decreased collagen fiber 
strength, and diminished tensile strength of the extracellular matrix, 
contribute to cervical softening and swelling (44-47). 
ASSESSMENT OF CERVICAL RIPENESS  
The Bishop score 
The degree of cervical ripeness is usually described by the Bishop score (48). 
The Bishop score, originally derived from multiparous women, utilizes 
cervical dilation, cervical effacement, cervical consistency, cervical position, 
and station relative to the ischial spines to estimate the degree of cervical 
ripeness (48). The initial scoring system by Bishop in 1964 used a maximum 
score of 13, with a score of 9 meaning that IOL and spontaneous labor were 
equally likely to result in vaginal delivery. In 1966, Burnett modified the 
Bishop score to the current form with each variable attributing 0−2 points to 
a maximum score of 10 (Table 1) (49). Friedman proposed a weighted score 
with cervical dilation having twice the influence of effacement, station, and 
consistency, and four times the influence of cervical position (50). Several 
later studies also emphasize cervical dilation as the most important 
contributor for success of labor induction, while consistency and position 
have the least predictive value (51-53). Later modifications of the Bishop 
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score, such as only using dilation, effacement, and station for determining 
cervical ripeness, have also been described (54). 
 
Table 1. Determining the Bishop score (0−10) (49). Bishop score < 6 indicates unripe cervix, 
and score ≥ 6 is used as a marker for ripened cervix 
 
Variable Score 
0 1 2 
Dilation (cm) 0 1−2 3−4 
Effacement (cm/%) >3/0−30% 1−3/40−50% <1/60−70% 
Consistency Firm Medium Soft 
Position Posterior Mid Anterior 
Station −3 or above −2 −1−0 
Transvaginal ultrasonography 
Transvaginal ultrasonographic parameters, such as cervical length, cervical 
wedging, and the distance from fetal head to perineum (Figure 1), have been 
suggested useful in the assessment of cervical ripeness and predicting the 
outcome of IOL (55, 56). A recent study found ultrasonography better 
tolerated than vaginal exam (55). According to a recent review and meta-
analysis of 735 pregnancies, a woman with ultrasonographic cervical length 
of ≤ 10 mm has an 85% chance of spontaneous delivery within a week (57). 
However, ultrasonographic assessment is not considered superior to vaginal 




Figure 1. Ultrasonographic measurements (cm) of cervical length (1), cervical wedging (2), 




Some studies suggest that the presence of cervical fetal fibronectin, derived 
from the chorionic-decidual membranes, may be associated with initiation of 
labor at term (59, 60). However, many studies show no predictive value over 
the Bishop score or ultrasonographic determination of cervical length (58). 
IGFBP-1 increases during pregnancy (61). Non-phosphorylated isoform of 
IGFBP-1 is the major protein in the amniotic fluid from the second trimester 
onwards, while decidual cells secrete phosphorylated isoforms (phIGFBP-1) 
(61, 62). Dogl et al. showed a correlation between an increased cervical 
IGFBP-1 concentration and spontaneous labor or successful IOL in post-term 
pregnancy (63). However, IGFBP-1 was not considered superior to cervical 
sonographic length or the Bishop score (63). PhIGFBP-1 reflects cervical 
ripeness, and the concentrations of cervical phIGFBP-1 increase during 
ripening induced with PG (64). Presence of cervical phIGFBP-1 was recently 
suggested to predict onset of spontaneous labor and vaginal delivery in term 
and post-term pregnancies (65). 
 
MMPs contribute to cervical ripening and initiation of labor at term (66, 67). 
The proteolytic or non-proteolytic effects of MMPs and their tissue inhibitors 
(tissue inhibitors of metalloproteinase, TIMPs) in the cervical mucus may 
include degradation of local extracellular matrix components, thereby 
enhancing cervical softening and affecting the overlying cervical membranes 
(68). The concentrations of MMP-8 and MMP-9 are higher during labor 
compared to pregnant women not in labor (69, 70). TIMP-1 and TIMP-2 
concentrations are also higher in the cervix during pregnancy compared to 
non-pregnant cervix (66), and increase in spontaneous labor (67). Also, an 
increase in TIMP-1 concentration has been observed during progressive 
cervical dilation in labor (45). The role of MMPs in assessing cervical 
ripeness is yet unknown. 
ONSET OF LABOR AT TERM 
 
An abundance of research regarding onset of parturition exists throughout 
the last century, yet the exact mechanism remains unclear. Multiple studies 
support the activation of inflammatory signaling pathways leading to 
increased secretion of cytokines and chemokines, uterine inflow of 
neutrophils and macrophages, production of uterotonins and uterine 
activation proteins including oxytocin receptors, and activation of MMPs 
(39-41). These biochemical processes may lead to cervical ripening, rupture 
of membranes, and myometrial contractions. Recently, cell-free fetal DNA, 
derived from placental trophoblasts and fetal membranes following 
apoptosis, has been suggested to trigger this inflammatory cascade and onset 
of labor (9, 10). The presence of cell-free fetal DNA in the maternal plasma, 
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as well as the presence of increasing placental and membrane apoptosis at 
term, supports the theory (71). Furthermore, recent studies provide evidence 
of increasing maternal serum concentrations of cell-free fetal DNA during 
the last weeks of gestation, with a peak just before parturition followed by a 
fall to undetectable levels by some hours postpartum (72). 
 
HISTORY AND TRENDS OF LABOR INDUCTION 
 
The concept of IOL has existed throughout recorded history, mechanical 
dilation of the cervix being the oldest induction method (73). Before the first 
century A.D., Hippocrates described the use of mammary stimulation and 
manual dilation of the cervical canal for labor induction (74). Methods of IOL 
have significantly evolved over the last century, improving safety and labor 
outcomes. Until 1931, IOL was carried out by surgical dilation of the cervix, 
including use of pressurized douches, laminaria tents, elastic cylinders 
(bougies), fluid-filled bags (de Ribes bags), early versions of balloon 
catheters, and even vaginal CS (74). The use of aggressive surgical 
procedures, associated with high rates of maternal mortality, rapidly 
decreased as medical options were developed (73). Also, amniotomy became 
the surgical method of choice by 1948 (73). Amniotomy was introduced in 
1810 by James, but was first avoided due to the belief that amniotic fluid loss 
endangered the fetus (73). Until 1955, high amniotomy (rupturing the 
membranes with a catheter and a metallic wire as high above the fetal head 
as possible) was preferred over low rupturing of the membranes, as 
preserving the membranes was thought to accelerate cervical dilation (74). 
 
The concept of cervical balloon catheter was first introduced by Gariel and 
Mattei in 1854 (75). The first balloons were made of rubber or sheep’s 
bladder, and were applied for cervical dilation after onset of labor. Mattei 
first described the intrauterine placement and traction of the catheter, while 
Storer suggested the use of water for balloon distension (75). Several 
improved versions of balloon catheters were developed during the end of the 
19th century (75). After pharmacological options were invented, the use of 
unhygienic and infection-prone balloon catheters decreased (75), until 
reintroduced by Embrey and Mollison in 1967 (76). 
 
The first pharmacological methods included ergot alkaloids, castor oil, 
quinine, and teratogenic stilboestrol (73). Oxytocin, extracted from the 
pituitary gland by Dale, was first used for IOL in 1909 (74). However, the 
method was first discarded, since the impurities and erratic intramuscular 
and subcutaneous administration resulted in increased adverse perinatal 
outcomes (73). In 1953, the formula of oxytocin was discovered, and 
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synthetic intravenous oxytocin gradually became a common pharmacological 
method for IOL (74). PGs, first introduced by Karim et al. in 1968, became 
commercially available for labor induction in 1980 (77). 
 
IOL is defined by the World Health Organization (WHO) as initiation of 
labor by artificial means prior to its spontaneous onset at a viable gestational 
age, with the aim of achieving vaginal delivery in a pregnant woman (3). An 
average of 20−30% of women undergo IOL in developed countries, and the 
incidence is rising worldwide (1-3). According to the European Perinatal 
Health Report, the rates of IOL vary between 7% and 32% in European 
countries (1). In the USA, the rates of IOL have more than doubled, from 
9.5% to 23.4%, during the last two decades (2). In the UK, the IOL rate has 
been relatively high over the past 20 years, with a modest increase from 
18.3% to 20.8% (78). A secondary analysis of the WHO Global Survey 
reported a 4.4% rate of IOL in African countries, while in Asia the IOL rate is 
12.1% (79). In Latin America, the rate of IOL is 11.4%, but the rates of CS are 
some of the highest in the world (80). 
 
In Finland, the rate of IOL has risen from 13.9% to 24.8% over the past 20 













The rates of IOL vary considerably between individual hospitals in Finland 
(10.5−38.6%, Figure 4) (4). In Helsinki University Hospital, the rate of IOL 
was 21.8% in 2015 (4). The differences between individual hospitals may be 
explained by differences in the proportions of maternal age, weight, and 
pregnancy complications, as well as different management practices and 
distances to the delivery unit. 
 
Figure 4. The average rates of labor induction in Finnish university hospitals (n=5, annual 
delivery rates 2441−14 476) and central hospitals (n=15, annual delivery rates 275−2955) 
during 2007−2015 (4). 
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INDICATIONS AND TIMING OF LABOR INDUCTION 
 
The decision on labor induction should be carefully weighed against the 
potential risks and benefits of continuing the pregnancy. Several clinical 
guidelines and recommendations on indications for IOL have been 
published, such as the WHO recommendations, the American College of 
Obstetricians and Gynecologists (ACOG) Practice Bulletin, the Clinical 
Practice Guidelines of the Society of Obstetricians and Gynaecologists of 
Canada (SOGC), and the National Institute for Health and Care Excellence 
(United Kingdom, NICE) guidelines (3, 5-7). Indications for IOL according to 
these guidelines are presented in Table 2 (3, 5-7). The most common 
indications for IOL are post-term pregnancy and term PROM, constituting 
50−60% of all inductions (1, 2, 8). Although labor is mostly induced for 
maternal or fetal indications, elective inductions for non-medical indications 
have also increased (8, 81). IOL may, for example, be considered for 
psychosocial or logistic reasons, such as maternal exhaustion or distance to 
delivery unit. However, each pregnancy should be assessed individually, 
considering maternal and fetal well-being, gestational age, risk factors, and 
cervical ripeness. 
 
Contraindications for IOL comprise vasa previa, complete placenta previa, 
transverse fetal lie, umbilical cord prolapse, pelvic structural deformity, 
invasive cervical carcinoma, previous uterine rupture, active primary genital 
herpes infection, previous classical CS, history of more than one previous CS, 
and uterine surgery entering the endometrial cavity (3, 5-7). According to the 
NICE guidelines, severe fetal growth restriction (FGR) with confirmed fetal 
compromise should also be considered a contraindication for IOL (7). 
Furthermore, the existing guidelines for IOL in breech presentation are 
controversial. The SOGC guidelines do not recommend IOL (6), while the 
NICE guidelines state that IOL in breech presentation should not be 
routinely offered but may be considered after discussing the potential risks 
with the woman (7). The ACOG and most European national guidelines have 
no recommendation on the topic, while IOL in breech presentation is in some 
hospitals practiced with careful clinical criteria (82). The few existing studies 
with sample sizes of 13−73 pregnancies have reported favorable maternal 









Table 2. Indications for labor induction according to the guidelines of WHO, ACOG, SOGC, 











pregnancy Post-term pregnancy 
Post-term 
pregnancy Post-term pregnancy  
PROM PROM PROM PROM 





  Preeclampsia  Preeclampsia Maternal request 
  Chorionamnionitis Chorionamnionitis   
  Gestational hypertension 
Antepartum 
hemorrhage   
  Placental abruption Diabetes mellitus   
 Maternal disease¹ Maternal disease¹  
  Fetal compromise² Fetal compromise²   
  Logistic reasons³ Twin pregnancy ≥ 38 weeks   
  Logistic reasons3  
¹Diabetes, hypertension, renal disease, chronic pulmonary disease. ²Severe fetal growth restriction, 
isoimmunization, oligohydramnios.  ³Fear of rapid labor, psychosocial reasons, distance from hospital 
POST-TERM PREGNANCY 
 
Post-term pregnancy is defined as a pregnancy extending to ≥ 42⁺⁰ weeks (≥ 
294 days) (85). Approximately 5% of pregnancies continue post-term (1, 85). 
The incidence of post-term pregnancy depends on pregnancy dating, fetal 
monitoring, management protocols, number of elective CSs, and population 
characteristics, such as genetic predisposition and pregnancy complications. 
Known risk factors for post-term pregnancy include nulliparity, age > 30 
years, low socioeconomic status, prior post-term pregnancy, male fetus, and 
white ethnic origin (86-88). In Finland, 8−10% of pregnancies extend 
beyond 41 weeks of gestation, and the rate of post-term pregnancy has 





Figure 5. The rates of post-term pregnancies (≥ 42 weeks) in Finland during 1995−2015 (4). 
 
 
In the Nordic countries, the rate of post-term pregnancy is the lowest (1.9%) 
in Denmark, and the highest (7.1%) in Sweden (Figure 6) (89). The rates of 
post-term pregnancy have decreased in Norway and Iceland, perhaps due to 










Post-term pregnancy is associated with increased risk of perinatal mortality 
and morbidity, including placental failure, meconium aspiration, shoulder 
dystocia, macrosomia, and fetal asphyxia (32, 33). The risk of stillbirth in 
post-term pregnancy is twice as high as at term, and more than sixfold at 43 
gestational weeks (85). After term, the risk of stillbirth increases tenfold in 
fetuses with growth restriction or oligohydramnios as a consequence of 
placental failure, and in these cases IOL is recommended by term (90). For 
the neonate, post-term pregnancy is also a risk factor for death in the first 
year of life as well as for cardiovascular and metabolic diseases later in 
adulthood (91, 92). The rates of maternal adverse outcomes and operative 
deliveries also increase with increasing gestational age beyond 40 weeks (32, 
33). 
 
The Cochrane review (n=9383) concluded that IOL at 41 gestational weeks 
results in improved perinatal outcomes without increasing the rate of CS 
(31). A Danish national cohort study (n=832 935) reported a decrease in risk 
of stillbirth after introducing a more proactive induction policy in Demark 
(28). Women with increased risk of stillbirth, such as women with body mass 
index (BMI) > 30, women > 40 years of age, and women with a pregnancy 
complication, were induced by 41 gestational weeks (28). In a recent review 
of 157 randomized controlled trials (RCTs) (n=31 085), the rates of CS, 
stillbirth, and neonatal intensive care episodes decreased following IOL at 40 
gestational weeks compared to expectant management (27). Furthermore, a 
retrospective cohort study comparing the outcomes of elective induction and 
expectant management in 1 271 549 women with gestational age of 37−41 
weeks, suggests that IOL can reduce perinatal mortality without increasing 
maternal complications (93). 
TERM PREMATURE RUPTURE OF MEMBRANES 
 
Term PROM occurs in approximately 8% of pregnancies (94). PROM is 
defined as rupture of membranes at least one hour before the onset of 
contractions. Sixty percent of the women with PROM deliver spontaneously 
within 24 hours (95). Prolongation of the onset of labor for more than 24 
hours is associated with an increased incidence of chorionamnionitis and 
neonatal sepsis (95, 96). The TERMPROM trial (n=1670) also reported less 
chorionamnionitis and neonatal infections following IOL by oxytocin 
compared to IOL with vaginal PGs (95). The management guidelines for 
PROM recommend immediate IOL as well as expectant management for 24-
48 hours (94, 97, 98). 
 
PROM is also a risk factor for Group B streptococcus (GBS) infection (95). 
GBS is the leading cause of early neonatal sepsis, and also associated with 
maternal peripartum infections (99). Approximately 10−30% of pregnant 
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women are GBS-positive (99). The TERMPROM trial reported a higher rate 
of neonatal infections in GBS-positive women managed expectantly after 
PROM compared to IOL (95). A recent cohort study of 542 women showed 
similar rates of infections in GBS-positive and GBS-negative women 
following membrane stripping (100). Studies on FC induction in GBS-
positive women are non-existent. A small cohort study (n=45) reported an 
increase in GBS-colonization during FC retention, but the relation to 
maternal or neonatal infections was not assessed (101). 
PREGESTATIONAL AND GESTATIONAL DIABETES 
 
Approximately 1% of pregnancies are complicated by pregestational type 1 or 
type 2 diabetes mellitus, and the incidence is rising with increasing rates of 
maternal obesity (1, 2). In Finland, pregestational diabetes is present in 
approximately 350 (0.6% in 2015) pregnancies annually (4). Pregestational 
diabetes is accompanied by increased risk of pregnancy complications, such 
as preeclampsia, diabetic ketoacidosis, progression of diabetic nephropathy 
or retinopathy, macrosomia, shoulder dystocia, stillbirth, and perinatal 
morbidity (102). Timing of IOL is based on glycemic control and possible 
maternal or fetal complications. In case of suboptimal glycemic control or 
maternal cardiovascular disease, IOL is supported at 37−39 gestational 
weeks (103). 
 
The incidence of gestational diabetes mellitus (GDM) is also steadily 
increasing (4). In Finland, 16% of pregnant women were diagnosed with 
GDM in 2015 (4). A 2-hour oral glucose tolerance test with diagnostic blood 
glucose values of 5.3 (fasted glucose) – 10.0 (1 h) – 8.6 (2 h) mmol/L has 
been used in Finland since 2008, but screening criteria, sampling technique, 
and diagnostic values vary around the world (104). If complicated by poor 
glycemic control and fetal macrosomia, GDM increases the risk of fetal 
asphyxia and perinatal complications (105, 106). Women with insulin 
dependent GDM have an almost fivefold risk of fetal macrosomia compared 
to women with dietary treatment (107). 
 
In insulin dependent and drug therapy dependent GDM, the Cochrane 
review as well as the Finnish national Current Care Guidelines recommend 
IOL at 38−40 gestational weeks due to an increased risk of fetal asphyxia, 
macrosomia, and shoulder dystocia (104, 108). However, if the estimated 
fetal weight exceeds 4500 g, an elective CS is recommended (104). 
 
In non-insulin dependent GDM, routine IOL is not supported unless poor 
glycemic control or complications, such as fetal macrosomia or placental 
failure, occur (104, 108, 109). On the other hand, a recent population-based 
study on 8392 women with non-insulin dependent GDM demonstrated a 
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decrease in CS rate following routine IOL at 38−39 gestational weeks 
compared to expectant management (110). However, IOL before 39 
gestational weeks increased the risk of neonatal intensive care unit (NICU) 
admission (110). Similar results were reported by a secondary analysis 
comparing IOL between 37 and 40 gestational weeks and expectant 
management in women with non-insulin dependent GDM (111). This study 
also observed a threefold increase in CS rate following IOL beyond 41 
gestational weeks compared to IOL at 39 weeks of gestation (111). 
 
Fetal macrosomia, defined as birth weight greater than 4000−4500 g, is 
associated with maternal and neonatal complications including shoulder 
dystocia, operative delivery, and postpartum hemorrhage (112). In Finland, 
13.7% of newborns were 4000−4500 g of weight and 2.3% were over 4500 g 
of weight in 2015 (4). In case of macrosomia and maternal GDM, IOL is 
recommended at 38−40 gestational weeks, and elective CS is recommended 
if fetal weight exceeds 4500 g (104, 108). An abundance of studies and 
current clinical guidelines do not support IOL in case of non-diabetic fetal 
macrosomia, but increased rates of CS have been reported (104, 112-114). 
However, contradicting results have also been reported. Cheng et al. found 
lower rates of CS in women undergoing IOL at 39 gestational weeks 
compared to women delivering at later gestational age, with infants of birth 
weight 4000 g or more (115). Moreover, a recent multicenter RCT of 822 
women demonstrated a decreased risk of shoulder dystocia and perinatal 
morbidity without an increase in CS rate, when labor was induced at 37−39 
weeks of gestation compared to expectant management (116). 
HYPERTENSIVE DISORDERS 
 
Chronic hypertension complicates approximately 1−5% of pregnancies, and 
the incidence is increasing with advancing maternal age and obesity. Chronic 
hypertension is associated with pregnancy complications including 
preeclampsia, maternal stroke, FGR, stillbirth, and CS (117). RCTs on 
optimal timing of IOL in these pregnancies are non-existent. A Canadian 
cohort study on 171 669 women recommended IOL at 38−39 weeks in non-
medicated chronic hypertension, and at 37 weeks in case of medication (118). 
A Dutch birth register study supported IOL by 38−40 weeks in pregnancies 
complicated by maternal chronic hypertension (119). 
 
The incidence of gestational hypertension varies between 2% and 17%. 
Pregnancy outcomes in women with mild gestational hypertension are 
similar to pregnancy outcomes of normotensive women (120, 121). Severe 
gestational hypertension is associated with an increased risk of FGR and 
placental abruption, and almost 50% of these women develop preeclampsia 
(121, 122). The existing literature supports IOL in gestational hypertension, 
 
28 
yet the optimal timing remains unclear. A retrospective cohort study found 
the lowest risk of maternal morbidity and mortality with IOL at 38 
gestational weeks, and the lowest risk of neonatal morbidity at 39 gestational 
weeks (123). A Dutch RCT (the HYPITAT-II trial) comparing pregnancy 
outcomes between IOL and expectant management in 703 women with 
hypertensive disorder at 34−37 weeks of gestation, found no significant 
difference in maternal adverse outcomes, such as thromboembolic 
complication, pulmonary edema, eclampsia, HELLP syndrome, or placental 
abruption (124). The study concluded that IOL is recommended between 34 
and 37 weeks of gestation, considering maternal and fetal well-being, and the 
risk of fetal respiratory distress syndrome (RDS) (124). On the other hand, 
Barton et al. reported increased rates of neonatal complications in women 
with gestational hypertension undergoing IOL at 34−36 gestational weeks 
(125). A recent retrospective cohort study on 114 651 low risk women 
reported an increased risk of CS and maternal morbidity in expectant 
management compared to elective IOL at term (126). 
 
The incidence of preeclampsia, one of the leading causes of maternal 
mortality worldwide, is approximately 5% (127). Preeclampsia is associated 
with placental abruption, maternal kidney and liver failure, intracranial 
hemorrhage, pulmonary edema, FGR, and neonatal morbidity and mortality 
(128). The randomized HYPITAT trial (n=756) reported a 13% decrease 
(relative risk [RR] 0.71, 95% confidence interval [CI] 0.59−0.86; p<0.0001) 
in maternal morbidity when labor was induced by 37 gestational weeks 
compared to expectant management in cases of preeclampsia with no severe 
complications (129). Neonatal outcomes did not differ between the groups 
(129). In cases of eclampsia, immediate labor after stabilization of maternal 
condition is recommended regardless of the gestational age (130). 
FETAL GROWTH RESTRICTION AND OLIGOHYDRAMNIOS 
 
FGR is associated with an increased risk of stillbirth and perinatal mortality, 
particularly for fetuses with estimated weight less than the fifth percentile. 
ACOG management guidelines recommend delivery at 38−40 weeks, and 
earlier if additional fetal or maternal complications are present (131). In 
previous observational studies on FGR, IOL has been associated with 
demonstrable benefit in neonatal outcomes (132-134). In cases of isolated 
FGR or small for gestational age fetus, IOL before 37 gestational weeks has 
not been shown to improve neonatal outcomes but has been linked to 
increased rates of CS and neonatal complications (135-137). The randomized 
DIGITAT trial (n=650) on isolated FGR concluded that IOL after 38+0 
weeks appears the option of choice for preventing neonatal morbidity and 
stillbirth, with no increase in CS rate (138). A follow-up analysis of the 
DIGITAT trial reported comparable neonatal morbidity rates, and concluded 
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that IOL after 38 weeks may prevent stillbirths (139). The 2-year follow-up 
study noted no differences in developmental outcomes in the DIGITAT 
children (140). A recent cost analysis of the DIGITAT study found no 
improvement or economic benefit in outcomes with expectant management 
beyond 38 weeks of gestation (35). 
 
Oligohydramnios is defined as an amniotic fluid index (AFI) less than 5 cm 
or a single deepest amniotic fluid pocket smaller than 2 cm (141). Higher 
rates of IOL have been reported when AFI is used for diagnoses of 
oligohydramnios compared to the single deepest amniotic fluid pocket (142). 
Oligohydramnios may occur as an idiopathic finding, but it may also be 
associated with FGR, fetal congenital anomalies, and multiple gestations 
(143). In post-term pregnancy, oligohydramnios may be related to placental 
failure leading to increased risk of fetal distress and perinatal mortality, and 
IOL is recommended (144). In case of isolated oligohydramnios with no 
pregnancy complication, IOL prior to term is not considered beneficial (145, 
146). 
OTHER INDICATIONS 
Intrahepatic cholestasis of pregnancy 
Intrahepatic cholestasis of pregnancy, a condition of unknown etiology with 
elevated serum bile acids and pruritus, occurs in approximately 1−1.5% of 
pregnancies in western countries (147-149). The risk of maternal 
complications is insignificant, while the risk of stillbirth increases 1−3% with 
increasing maternal serum bile acid concentration (especially > 100 μmol/L) 
and gestational age (150). Maternal elevated serum bile acids may cause 
placental vasoconstriction, fetal cardiac rhythm disorders, and increased 
myometrial sensitivity to oxytocin, thus possibly compromising the fetal 
well-being (151-153). Other risks associated with intrahepatic cholestasis 
include meconium-stained amniotic fluid, preterm delivery, and RDS. 
Literature supports IOL at 37−40 gestational weeks in pregnancies 
complicated by cholestasis, but RCTs and evidence-based management 
guidelines on optimal timing of IOL are unavailable. A case-control study 
comparing expectant management and IOL at 38 gestational weeks in 320 
women with intrahepatic cholestasis, reported similar perinatal mortality 
rates (1.8% vs. 1.3%) in both groups (148). Another case study (n=206) 
reported lower rates of stillbirth (0% vs. 1.6%; p=0.05) when labor was 
induced by 37 gestational weeks in women with intrahepatic cholestasis 
compared to those induced later (154). A recent decision-analytic model 
applied to 18 studies with an average perinatal mortality rate of 1.7% found 
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36 gestational weeks was an optimal time for IOL, considering the risks of 
perinatal mortality and the risks of preterm birth (155). 
Twin gestations 
The rate of twin gestations in Finland was 1.3% in 2015 (4). A recent 
retrospective cohort study comparing outcomes between 100 twin and 100 
singleton pregnancies found no difference in CS rates following IOL (156). A 
cohort study on planned vaginal deliveries ≥ 34 weeks reported a twofold risk 
of CS in women undergoing IOL compared to women with spontaneous onset 
of labor (21% vs. 12%; p<0.001) (157). However, vaginal delivery rate of 80% 
following IOL was reported (157). On the other hand, a multicenter RCT on 
235 uncomplicated monochorionic or dichorionic twin pregnancies found a 
significant reduction in adverse outcomes without an increase in CS rate 
following IOL at 37 gestational weeks, compared to expectant management 
and IOL at 38 gestational weeks (158). The recent Cochrane review also 
supported IOL at 37 gestational weeks in dichorionic twin gestations (159). 
Furthermore, a recent systematic review and meta-analysis on 29 685 
dichorionic twin and 5486 monochorionic twin pregnancies concluded that 
considering risk of perinatal mortality, IOL is recommended at 37 gestational 
weeks in uncomplicated dichorionic pregnancy, and at 36 weeks of gestation 
in monochorionic pregnancy. NICE guidelines recommend IOL at 35 weeks 
of gestation in monochorionic twin gestations (160). 
TIMING OF LABOR INDUCTION 
 
The optimal timing of IOL has been extensively studied in some cases, such 
as post-term pregnancy, while only limited data are available for other 
clinical situations. Table 3 summarizes the optimal timing of IOL according 
to the current recommendations by WHO, ACOG, SOGC, and NICE (3, 5-7), 















Table 3. Timing of labor induction summarized from the recommendations of WHO, ACOG, 
SOGC, and NICE (3, 5-7). The gestational weeks refer to completed weeks. Quality of 
evidence is determined by the recent review on timing of IOL in the following way: a = high, 
b = moderate, c = low, d = very low (103). 
 
Indication for labor 
induction Timing of induction 
Quality of 
evidence 
Post-term pregnancy 41−42 weeks a 
PROM Immediate to 48 hours a 
Intrauterine growth 
restriction 
38−39 weeks.  
Earlier if fetal or maternal complications b 
Oligohydramnios 39−40 weeks c 
Pregestational diabetes 37−39 weeks (depending on glycemic control, fetal complications, maternal cardiovascular disease) c 
Insulin-dependent 
gestational diabetes 38−39 weeks c 
Non-insulin dependent 
gestational diabetes 
Not recommended1  
38−40 weeks if poor glycemic control, macrosomia, 





Chronic hypertension 38−40 weeks, 37 weeks if medication c 
Gestational hypertension 38−39 weeks b 
Mild preeclampsia without 
severe features 37 weeks b 
Severe preeclampsia with 
severe features Latest 34 weeks b 
Eclampsia Immediate after stabilization c 
Intrahepatic cholestasis of 
pregnancy 36−39 weeks d 
Dichorionic twins 37−38 weeks b 
Monochorionic-diamniotic 
twins 34−36 weeks c 
1Melamed et al. 2016 and Sutton et al. 2014 support routine IOL at 38−39 weeks (110,111) 







METHODS OF LABOR INDUCTION 
 
In women with unfavorable cervices (Bishop score < 6), IOL is started with 
mechanical or pharmacological cervical ripening, whereas with ripened 
cervix, typically marked by Bishop score ≥ 6, amniotomy and oxytocin will be 
considered for IOL. In Finland, balloon catheters and misoprostol are 
presently available for cervical ripening depending on maternal and fetal 
factors, such as IOL indication and history of previous CS. 
MECHANICAL CERVICAL RIPENING BY BALLOON CATHETERS 
 
Single balloon catheters, including FC, and double balloon catheters are 
available for cervical ripening. The mechanism of balloon catheter induced 
cervical ripening consists of direct mechanical stretching of the cervix and 
lower uterine segment, and stimulation of endogenous PG release following 
separation of the chorionic membrane and decidua (14, 15). Mechanical 
stretching of the cervix also augments production of hyaluronic acid, which 
may enhance cervical swelling and softening (161). In addition, myometrial 
stretching increases expression of cyclooxygenase-2 (COX-2) and production 
of PGs (162). Another potential mechanism enhancing cervical softening, is 
the stimulation of inflammatory cytokine secretion, such as interleukins and 
MMPs (163). 
 
A balloon catheter is inserted through the cervical canal into the space 
between the amniotic membrane and lower uterine segment digitally or by 
direct visualization during a speculum examination. Digital insertion is 
performed by placing a finger on either side of the cervical opening during 
vaginal examination, then guiding the tip of the catheter into the cervix and 
pushing it through the cervical canal with a dominant hand. In instrumental 
insertion, a speculum is inserted into the vagina to gain access to the cervix, 
and the catheter is guided through the cervical canal. Double balloon 
catheters include a stylette for insertion, while single balloon catheters may 
be guided through the cervical canal by holding it with forceps. After 
ensuring the tip of the catheter lies above the internal cervical os, the balloon 
is inflated with 30−80 ml of saline, and retracted to rest on the internal 
cervical os (Figure 7). In addition to the uterine balloon, a double balloon 
catheter includes a cervicovaginal balloon, which is inflated with a maximum 
of 80 ml saline after uterine balloon inflation (Figure 8). With a single 
balloon catheter, traction is applied by using a 500 mg weight or taping onto 
the inner thigh, whereas the two balloons of the double balloon catheter 
create cervical compression and traction is not required. Following expulsion 




Figure 7. A single balloon catheter is inserted through the cervical canal into the space 








Insertion of a balloon catheter may be challenging and cause discomfort in 
women who are nulliparous or have a low Bishop score (165), although a 
learning curve for catheter insertion has been demonstrated (166). Digital 
insertion is faster and causes less discomfort than instrumental insertion 
(167). A recent RCT showed that insertion with a stylette is comparable to 
insertion without a stylette in pain score, insertion time, and misplacement 
(168). During a balloon catheter insertion, cervical bleeding may occur in 
2−6% of women (165, 169). Higher balloon volume (60−80 ml) results in 
greater cervical dilation, with no difference in the mode of delivery or 
induction to delivery interval compared to a lower 30 ml volume (164, 170). 
Application of traction on the catheter, particularly by using a weight (500 
mg) compared to inner thigh taping, may speed up balloon expulsion by 1−2 
hours (171, 172). 
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Use of balloon catheter for cervical ripening is supported by the WHO, 
ACOG, SOGC, and NICE guidelines (3, 5-7). No increase in maternal or 
neonatal infectious morbidity has been associated with FC cervical ripening 
(16, 18, 173), although contradicting results have also been presented by one 
older study (174). 
 
Two RCTs reported similar efficacy in single and double balloon catheters for 
cervical ripening, but lower pain scores and shorter induction to delivery 
interval were reported when using a single balloon catheter (20, 175). 
Another RCT reported a higher rate of adverse labor outcomes associated 
with the use of double balloon catheter (176). 
PHARMACOLOGICAL CERVICAL RIPENING BY PROSTAGLANDINS 
 
PGs, cyclopentane derivatives of arachidonic acid, stimulate remodeling of 
cervical collagen, and act within the uterine myocytes, increasing 
contractility (177). Two synthetic forms of PG, prostaglandin E1 (PGE1) 
analogue misoprostol and prostaglandin E2 (PGE2) analogue dinoprostone, 
are available for cervical ripening. Dinoprostone is the only PG approved by 
the US Food and Drug Administration for labor induction. Misoprostol, 
originally developed for gastric protection, is unlicensed for labor induction 
in most countries. However, off-label use has become common practice with 
a large quantity of research and clinical experience supporting its safety and 
efficacy. Misoprostol is considered more effective than dinoprostone in 
achieving vaginal delivery (178-182). On the other hand, concerns about 
higher rate of hyperstimulation and fetal heart rate changes with the use of 
misoprostol have been raised. However, the risk of hyperstimulation is 
dependent on the dose and administration route of misoprostol, with high 
doses and vaginal administration being associated with higher risk of 
hyperstimulation, while with lower oral (20−25 μg) doses the risk is similar 
to that detected with the use of dinoprostone (182). The ACOG, SOGC, and 
WHO approve the use of misoprostol, and it is currently the only 
prostaglandin analogue in obstetric use in Finland (3, 5, 6). In contrast, the 
NICE guideline recommends dinoprostone as the method of choice, and use 
of misoprostol only in cases of intrauterine fetal death (7). 
Misoprostol 
Oral administration of misoprostol has a faster rate of metabolism, but the 
overall exposure to drug is greater in vaginal administration. When 
administered orally, maternal plasma concentration of misoprostol acid rises 
rapidly, reaching peak concentration in 30 minutes, and then declining until 
120 minutes (Figure 9) (183). Therefore, repeated oral doses may be required 
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to induce regular uterine contractions. Vaginal application results in slower 
increase of plasma concentration, with a lower peak in 70−80 minutes, and a 
slow decline in 4−6 hours (Figure 9) (183). Vaginal absorption can be altered 
by the presence of blood or amniotic fluid (184). The most common maternal 
side effects of misoprostol are diarrhea, nausea, fever, and shivering (184). 
 
Misoprostol is commercially available in 100 μg and 200 μg scored tablets, 
and vaginal inserts. Because oral doses are metabolized faster than vaginal 
doses, safe and efficacious doses of orally administered misoprostol have 
been documented as double the vaginal dose. Clinically acceptable doses of 
misoprostol are 25 μg vaginally or 50 μg orally every 4 hours (182, 185-187). 
The WHO recommends use of 25 μg of misoprostol either orally every 2 
hours, or vaginally every 4 hours (188). Administration of misoprostol 
requires tablet cutting, which may lead to unstandardized doses and 
confusion. 
 
Misoprostol 200 μg vaginal insert is a removable, controlled-release vaginal 
delivery system releasing 7 μg of misoprostol hourly for a maximum of 24 
hours. The peak of plasma concentration of misoprostol acid is reached in 4 
hours, with a quick elimination after 3 hours from removing the insert 
(Figure 9) (189). Use of misoprostol vaginal insert appears to lead to shorter 
induction to delivery interval, lower rate of oxytocin augmentation, and an 
increased rate of uterine hyperstimulation, compared to the use of 
dinoprostone insert (190). So far, no studies comparing the use of 
misoprostol tablet and insert are available. 
 
 
Figure 9. Pharmacokinetics of misoprostol administered by oral or vaginal tablet or by 
vaginal insert (183, 189). 
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Various studies confirm that misoprostol is effective for IOL, but the optimal 
dose and route of administration remain controversial. According to a recent 
systematic review and network meta-analysis on 280 RCTs (n=48 068), low 
dose (< 50 μg) oral solution appears the safest in terms of risk of CS, while 
vaginal tablet (≥ 50 μg) seems the most effective in achieving vaginal delivery 
within 24 hours (186). The Cochrane review found that oral misoprostol was 
equally effective as vaginal misoprostol, but was associated with fewer cases 
of uterine hyperstimulation, 5-minute Apgar score < 7, and postpartum 
hemorrhage, and endorsed the use of oral misoprostol as the method of 
choice (182). Oral administration may also reduce the need for vaginal 
examinations, thereby reducing the risk of ascending infection in cases of 
PROM (191). According to the ACOG, SOGC, WHO, NICE, and the Cochrane 
review, misoprostol is not recommended for IOL in women with a history of 
previous CS or other uterine surgery due to an increased risk of uterine 
rupture (3, 5-7, 182). 
SEQUENTIAL AND COMBINED USE OF FOLEY CATHETER AND 
MISOPROSTOL 
 
A case-control study comparing 100 women with sequential use of 30 ml FC 
for 6 hours followed by 50 μg of misoprostol vaginally every 6 hours, and 50 
μg of vaginal misoprostol alone every 6 hours, reported more vaginal 
deliveries, shorter duration of labor, and less need for oxytocin augmentation 
in the combination group (192). Similarly, of 1030 women who underwent 
subsequent cervical ripening by a 50 ml FC following 24 hours of 
misoprostol, more than 80% of the women delivered vaginally (193). 
However, a recent retrospective cohort study of 862 women concluded that 
need for subsequent cervical ripening after use of vaginal PG was associated 
with a high (51%) risk of CS, particularly in nulliparous women (194). 
 
Three RCTs have reported that the combination of FC and oral (100 μg every 
4−6 hours) or vaginal (25−50 μg every 4 hours) misoprostol results in a 
shorter induction to delivery interval than misoprostol induction alone, with 
no increase in labor complications or adverse maternal or neonatal outcomes 
(195-197). Another recent RCT (n=491) reported that the combination of FC 
(30 ml for maximum of 12 hours) and misoprostol (25 μg vaginally every 3 
hours) resulted in twice the chance of vaginal delivery compared to either 
method alone, with no difference in delivery outcomes (hazard ratio 1.92, 
95% CI 1.42–2.59) (198). The induction to delivery interval was also shortest 
following the use of a combination of FC and misoprostol compared to FC or 
misoprostol alone (13 h vs. 18 h vs. 18 h; p<0.001) (198). Additionally, the 
recent Cochrane review demonstrated that the addition of FC to PG increases 
the likelihood of vaginal delivery within 24 hours with comparable rates of 
CS (199). Furthermore, uterine hyperstimulation with fetal heart rate 
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changes was less frequent in the combination group (199). In contrast, a 
meta-analysis found increased rates of chorionamnionitis associated with the 
combination method compared to misoprostol induction alone (200). 
COMPARISON OF FOLEY CATHETER AND MISOPROSTOL FOR 
CERVICAL RIPENING 
 
Vaginal delivery rates following the use of FC and PG are comparable, as well 
established by several RCTs (17-20, 173). An abundance of studies also 
demonstrate that FC and PGs have comparable neonatal primary outcomes 
(20, 173, 201, 202). The RCTs comparing FC and misoprostol for cervical 
ripening over the last decade are summarized in Table 4.  
 
Table 4. The RCTs from 2006–2016 comparing FC and misoprostol for cervical ripening 
(17-19, 203-205). No significant differences in adverse maternal or neonatal outcomes were 
found between treatment arms in any of these studies. Two trials including women with a 
previous CS (206), or pregnancies with fetal compromise (207) are not included. 










Prager et al. 
2008 (19) 397 




25 μg  
vaginally 
every 4 h 
(n=199) 
78 vs. 72 
(NS) 
2 vs. 6 
(NS) 
13 vs. 17 
(NS) 
Moraes Filho 
et al. 2010 
(204)1 
240 





every 6 h 
(n=119) 
64 vs. 73 
(NS) 
3 vs. 4 
(NS) − 
Vahid et al. 
2011 (203) 108 
50 ml, max. 
12 h (n=59) 
25 μg 
vaginally 
every 4 h 
(n=49) 
63 vs. 90 
(<0.01) 
0 vs. 2 
(NS) − 
Kandil et al. 
2012 (205) 100 
30 ml, max. 
12 h (n=50) 
25 μg 
vaginally 
every 4 h 
(n=50) 
76 vs. 80 
(NS) 
0 vs. 3 
(NS) 
6 vs. 6 
(NS) 
Jozwiak et al. 
2014 (17) 109 
30 ml, max. 
24 h (n=56) 
25 μg 
vaginally 
every 6 h 
(n=64) 
75 vs. 83 
(NS) 
4 vs. 2 
(NS) − 
Ten Eikelder  
et al. 2016 (18) 1859 
30 ml, 
max. 48 h 
(n=927) 
50 μg orally 
every 6 h, 
max. 3/24 h 
(n=932) 
80 vs. 83 
(NS) 
4 vs. 4 
(NS) 
4 vs. 3 
(NS) 
1In the study by Moraes Filho et al. 2010 (204), oxytocin alone was used following expulsion of FC, 




Only one Iranian study found a lower vaginal delivery rate with the use of FC 
(203), while the other studies reported similar rates (Table 4) (17-19, 204, 
205). No significant differences in adverse maternal or neonatal outcomes 
were found between treatment arms in any of these studies (17-19, 203-205). 
 
A recent review and meta-analysis comparing FC and misoprostol for IOL 
(n=4234) found no difference in the rates of CS, but concluded that FC was 
associated with better safety outcomes, such as less hyperstimulation, fewer 
vaginal instrumental deliveries, and fewer CSs for non-reassuring fetal heart 
rate (25). The recent Cochrane review (n=9722) also concludes that balloon 
catheters are associated with lower risk of hyperstimulation compared to PG 
(199). A review and network meta-analysis on 96 RCTs (n=17 387) 
comparing misoprostol, FC, and dinoprostone, concluded that no method 
showed overall superiority (181). Vaginal misoprostol was considered the 
most effective, but was associated with the highest rate of uterine 
hyperstimulation and fetal heart rate changes (181). FC was associated with 
the lowest rate of hyperstimulation, while oral misoprostol was associated 
with the lowest CS rate (181). 
 
Compared to spontaneous labor, FC IOL in women with a history of previous 
CS is associated with lower risk of uterine rupture (odds ratio [OR] 0.47, 95% 
CI 0.06−3.59) (23) than use of dinoprostone (OR 14.1, 95% CI 3.4−309.6) 
(208). The reported incidence of uterine rupture following one previous CS 
ranges between 0.3% and 1.1% in spontaneous labor, between 0.4% and 1.6% 
in FC induced labor, and between 0.3% and 2.9% in IOL with PG (Table 5) 
(21-23, 208-212). In women with previous CS, vaginal delivery rates of 
56−71% have been reported following IOL by FC (21-23, 209), and 61−71% 
following IOL by dinoprostone (209, 211) (Table 5). 
 
Some older studies have investigated the use of misoprostol for IOL in 
women with a history of previous CS. In the RCT by Wing et al., comparing 
vaginal misoprostol and oxytocin for IOL in women with a history of previous 
CS, two uterine ruptures (12%) in the misoprostol group occurred after the 
enrollment of 17 women, and the trial was stopped (213). Five retrospective 
studies with small sample sizes (n=39−145) on a total of 378 women reported 
uterine rupture rates of 3.5−8.3% following the use of misoprostol in women 
with a history of previous CS (214-218). Due to the increased risk of uterine 
rupture or dehiscence, most clinical guidelines do not recommend IOL by 







Table 5. The rates of uterine rupture and vaginal delivery following spontaneous onset of 
labor, IOL by FC, and IOL by PGE2, in women with a history of one previous CS (n >100 per 
method group) (21-23, 208-212) 
Study (ref) Design N Spontaneous FC Dinoprostone 











Ravasia et al. 
2000 (209) Retrospective 26 868 0.5 78 0.8 61 2.9 61 
Lydon Rochelle et 
al. 20011  (208) Retrospective 20 095 0.5 − − − 2.4  
Landon et al. 
2004 (210) Prospective 17 898 0.4 − 0.9 − 1.4 − 
Bujold et al. 2004 
(23) Retrospective 2 479 1.1 78 1.6 56 − − 
Locatelli et al. 
2004 (211) Retrospective 310 0.3 82 − − 0.3 71 
Macones et al. 
2005 (212) Case control 25 005 − − − − 2.2 − 
Jozwiak et al. 
2014 (22) Retrospective 208 − − 0.4 71 − − 
Zaki et al. 2014 
(21) Retrospective 149 − − 0.0 68 − − 
1Misoprostol may have also been included during the last year of the study period 1987−1996, since it 
was introduced then; more detailed data not available. UR, Uterine rupture; VD, Vaginal delivery 
 
Misoprostol is inexpensive, stable at room temperature, and may also be 
used in the treatment of postpartum hemorrhage, making it particularly 
useful in poor resource settings (219). The advantages of FC are low cost, 
easy reversibility, feasibility in outpatient use, less need for continuous fetal 
monitoring during cervical ripening, and safety in a scarred uterus (21-24, 
220). 
 
Women’s experiences of duration of labor, pain during labor, general 
satisfaction with labor, and feelings of control and fear related to their 
expectations are comparable between women undergoing IOL by FC and 
women undergoing IOL by oral misoprostol (221). In the oral misoprostol 
group, 6% of the women would prefer the other method in future IOL, while 
in the FC group the corresponding rate was 12% (RR 0.70, 95% CI 





Amniotomy, artificial rupturing of the membranes, is used for introducing 
internal monitoring devices and for IOL in women with a favorable cervix 
(Bishop score ≥ 6) (222, 223). After excluding the presence of umbilical cord 
and blood vessels across the membranes, and ensuring the fetal head is no 
higher than two stations above the ischial spines, amniotomy is performed by 
rupturing the membranes with a crochet-like hook or fetal scalp electrode. 
Potential risks of amniotomy include umbilical cord prolapse, cord 
compression, ascending infection, and bleeding from fetal or placental 
vessels (224). 
 
Under normal conditions, amniotic membranes remain intact until full 
dilation in 70% of labors (225). Amniotomy is considered to result in a 
release of endogenous PG leading to cervical ripening and uterine 
contractions (226). In women who need oxytocin for adequate uterine 
contractions, the concentration of plasma PG metabolites is found to decline 
quickly to initial level (226). Amniotomy can be used for IOL as the sole 
method, or in combination with oxytocin (223). 
 
Although amniotomy and intravenous oxytocin are widely used in IOL, 
surprisingly little literature on the efficacy or safety of the method exists. The 
Cochrane reviews on amniotomy alone, and amniotomy combined with 
oxytocin for IOL, concluded that due to lack of data to support these 
methods, no recommendations for clinical practice could be made (223, 227). 
Early amniotomy at cervical dilation less than 4 cm may shorten induced 
labor (228). An RCT, comparing early amniotomy concomitant with oxytocin 
infusion and late amniotomy at 4 hours after oxytocin administration, 
concluded that early amniotomy was associated with a shorter labor (229). 
Similarly, a recent matched case-control study found early amniotomy within 
one hour of FC expulsion, shortening the expulsion to delivery interval by 3 
hours (10.6 h vs. 13.8 h; p<0.001) with no difference in the vaginal delivery 
rates (52% vs. 48%; p=0.30) (230). 
OXYTOCIN 
 
The uterine response to oxytocin gradually increases from 20 to 30 weeks of 
gestation, followed by a steady level until 37 gestational weeks, after which 
the uterine response rapidly rises again (231). Oxytocin stimulates uterine 
contractions by activation of receptor-operated calcium channels, and release 
of calcium from the sarcoplasmic reticulum (232). The myometrial sensitivity 
to oxytocin is determined by the concentration and binding kinetics of 
oxytocin receptors (232). The uterine response ensues after 3–5 minutes of 
intravenous oxytocin infusion, and a steady plasma concentration of oxytocin 
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is reached in 40 minutes (231). The half-life of oxytocin is short, 3−17 
minutes (231). Maternal side effects of oxytocin include hypotension, 
tachycardia, arrhythmias, nausea, vomiting, headache, and flushing (233). 
The main risk of oxytocin use is excessive uterine activity, which may lead to 
fetal distress (234). 
 
Oxytocin is typically used in women with a favorable cervix (Bishop score ≥ 
6), since oxytocin induction in case of an unfavorable cervix is associated 
with high rates of induction failure (235). Cervical dilation, nulliparity, 
obesity, and gestational age < 37 gestational weeks may diminish the 
response to oxytocin induction (236). Rupturing the amniotic membranes 
may further provoke the response to oxytocin (227, 237). According to 
previous studies, oxytocin receptors undergo desensitization to exogenous 
and endogenous oxytocin after prolonged stimulation, such as during labor 
induction (238). Some studies suggest that discontinuing oxytocin during the 
active phase of induced labor may improve outcomes (239, 240). In the RCT 
by Daniel-Spiegel et al. (n=104), the median duration of labor was similar in 
continued oxytocin and discontinued oxytocin groups (3.8 h vs. 3.1 h; 
p=007), and there were fewer CSs (12% vs. 6%) when oxytocin induction was 
stopped at the beginning of the active phase of labor (239). The recent RCT 
by Bor et al. (n=200) found that the duration of the median active phase of 
labor was prolonged by 41 (95% CI 11-75) minutes when oxytocin was 
discontinued after 5 cm of cervical dilation (median 125 minutes vs. 88 
minutes; p<0.001) (240). However, the incidence of fetal heart rate 
abnormalities (50% vs. 20%, RR 2.63; 95% CI 1.67–4.14; p<0.001) and 
hyperstimulation (12% vs. 2%, RR 5.62; 95% CI 1.28–24.65; p<0.008) was 
greater in the continued oxytocin group (240). The rates of CS and 
postpartum hemorrhage were similar between the groups (240). In the 
discontinued oxytocin group, oxytocin was administered in 36 women after a 
2-hour labor arrest, and 78% of them delivered vaginally (240). 
 
Various oxytocin protocols for IOL have been described in the literature. A 
recent cohort study demonstrated that significantly higher dose of oxytocin 
was needed for obese women than for lean women (241). The Cochrane 
review on oxytocin use in women with delay of labor compared a high 
starting dose (≥ 4 mU/min) of oxytocin to low dose oxytocin (< 4 mU/min), 
and concluded that high dose oxytocin may increase vaginal deliveries in 
women with delay of labor. However, the data were insufficient to draw 
conclusions on maternal and neonatal outcomes (242). An RCT comparing 
immediate and 4 hours delayed oxytocin following amniotomy in 206 parous 






Most complementary and alternative methods for IOL are recommended on 
the basis of traditional knowledge and empirical evidence. The scientific 
research and clinical evidence available are limited, except for membrane 
sweeping. Membrane sweeping, also called membrane stripping, may result 
in endogenous PG release following separation of the chorionic membrane 
and decidua. Several RCTs, as well as the Cochrane review, have shown that 
membrane sweeping reduces the rate of post-term pregnancy, and increases 
the rate of spontaneous labor in post-term pregnancy (243-246). 
 
Laminaria tents, made from seaweed or synthetic hydrophilic materials, are 
inserted intracervically to induce cervical stretching. The use of laminaria is 
not shown to be beneficial, and they potentially increase infectious morbidity 
(199, 247). 
 
Use of isosorbide mononitrate, relaxin, hyaluronidase, corticosteroids, and 
estrogens for IOL have been described in the literature. However, the existing 
data are scarce and inconclusive, with large pharmacological variation in 
different compounds and doses (179). The use of herbal remedies, such as 
raspberry leaf, blue cohosh, black cohosh, evening primrose oil, and castor 
oil, is not supported by scientific data (248). These remedies for IOL appear 
to not be beneficial, although no harm has been demonstrated in the use of 
raspberry leaf (248). On the other hand, castor oil and evening primrose oil 
may increase complications related to side effects of nausea, vomiting, and 
diarrhea (249, 250). Although no clinical trials exist, there is some evidence 
that blue and black cohosh should be avoided during pregnancy (251). 
Currently, the clinical evidence is insufficient for recommendations on the 
use of homeopathy as a method of labor induction (252). 
 
A number of RCTs and the recent Cochrane review found no significant 
differences in the duration of labor or the number of spontaneous labors 
following acupuncture (246, 253-255). The recent Cochrane review 
concluded that evidence is insufficient for assessing the effect of hypnosis for 
IOL (256). Only preliminary research on the use of reflexology for IOL is 
presently available. One RCT on 288 women stated that use of the shiatsu 
technique, a massage involving the physical body and the points of 
acupuncture, may be a safe alternative method for reducing the need for IOL 
in post-term pregnancy (257). Stimulation of nipples may cause a release of 
endogenous oxytocin, and some evidence supports its use for IOL (258). 
However, the Cochrane review states that since the safety of nipple 
stimulation cannot be fully evaluated based on the existing studies, it should 
not be considered for use in high risk populations (258). Although sexual 
intercourse may stimulate the onset of labor via oxytocin secretion, and PG 
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stimulation by the semen upon the cervix, the data are insufficient for 
conclusions to be made (259, 260). 
 




An abundance of research demonstrates the role of parity in IOL. Nulliparity 
increases the risk of prolongation of pregnancy, but it is also an independent 
risk factor for induction failure and CS regardless of the induction method 
(86, 261-263). 
 
The average age of pregnant women is steadily increasing in all western 
countries (264). In Finland, the proportion of nulliparous women ≥ 35 years 
of age was 20.4% in 2015 (4). The risk of perinatal death, hypertensive 
disease, gestational diabetes, placenta previa, placental abruption, and IOL 
are higher among women ≥ 35 years of age than among younger women 
(264, 265). A Canadian population-based study on 157 445 women 
demonstrated a CS rate of 38% in nulliparous women ≥ 35 years of age, and a 
50% rate in women ≥ 40 years of age (265). An RCT showed no difference in 
the rate of CS and perinatal outcomes between IOL at 39 gestational weeks 
and expectant management in women ≥ 35 years of age (266). 
 
In Finland, every third pregnant woman is overweight with a pre-pregnancy 
BMI of ≥ 25, and 13% of the women were obese (BMI ≥ 30) in 2015 (4). 
Obese women are at risk of multiple labor complications, such as failed IOL, 
prolonged labor, postpartum hemorrhage, and postpartum endometritis 
(267-270). A retrospective cohort study on 470 obese nulliparas reported an 
increased risk of CS (40% vs. 26%; p=0.02) and neonatal intensive care 
episodes (18 vs. 6%; p=0.01) in the women undergoing IOL compared to 
those with spontaneous onset of labor (268). Maternal height appears to be 
an independent predictor of success of IOL. Taller women are more likely to 
have a vaginal delivery (53), whereas shorter stature (< 155 cm, OR 1.1 per 
cm less in maternal height) is associated with induction failure and CS (263, 
271). 
 
A recent study suggests that women of black ethnic origin have a threefold 
risk of CS in induced labor compared to white and Asian women (272). In 
another study, black women showed a twofold increase in perinatal mortality 
rate at 40 and 41 gestational weeks compared to Caucasian women (273). 
Similar rates of induction failure across ethnicity were reported by the 
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secondary analysis of the misoprostol vaginal insert trial (274). However, 
white women (29%) and Hispanic women (24.5%) delivered less frequently 
by CS compared to black women (32.7%) (adjusted OR 0.87, 95% CI 
0.44−0.97, p=0.03)(274). Postpartum hemorrhage occurred more frequently 
in Hispanic women compared to black women and white women (OR 2.27, 
95% CI 0.23−0.82, p=0.02 vs. OR 3.69, 95%CI 0.14−0.51, p<0.001) (274). 
PREGNANCY RELATED FACTORS 
 
Cervical ripeness is considered the most important factor affecting the 
success of IOL. Low Bishop score < 5 is associated with high rates of 
induction failure and CS (11-13). Cervical dilation, effacement, and station 
are considered more important variables, while cervical consistency is less 
emphasized (51-53). Higher gestational age beyond 40 weeks is a significant 
risk factor for induction failure, CS, and perinatal complications (28, 31-33). 
A population-based cohort study described a CS rate of 49% in post-term 
nulliparous women (263). In line with these findings, several studies have 
demonstrated a lower risk of CS following IOL at 39−41 weeks compared to 
expectant management (27, 30, 31). Indication for IOL may impact the risk 
of CS. A recent retrospective cohort study on 796 women undergoing IOL 
reported that nulliparous women undergoing IOL for fetal indications, 
including oligohydramnios, post-term pregnancy, FGR, and macrosomia, 
were at increased risk of CS, with the total CS rate being 17% (275). Another 
factor associated with increased risk of CS was IOL after week 40+0 (275). 
 
An increasing number of women have a history of a previous CS. The CS rate 
in Finland was 15.9% in 2015, with 9.6% of the CSs being unplanned (4). The 
greatest predictors of success of trial of labor in women with a previous CS 
are a prior vaginal delivery and a nonrecurring indication, such as breech 
presentation, for the previous CS (276, 277). With a history of previous CS, 
vaginal delivery rates of 87% have been reported in women with previous 
vaginal delivery compared to 61% in those with no previous vaginal delivery 
(OR 4.2;95% CI 3.8−4.5) (277). IOL increases the risk of repeat CS compared 
to spontaneous labor, and success rates of 56−75% for vaginal delivery 







PROGRESS OF INDUCED LABOR 
A cohort study on 5288 women concluded that women undergoing IOL have 
a significantly longer latent phase of labor than women with spontaneous 
onset of labor (median 5.5 h vs. 3.8 h; p<0.001 for nulliparous women, and 
4.4 h vs. 2.4 h; p<0.01 for multiparous women, Figure 10) (280). However, 
during the active first stage of labor, at ≥ 6 cm cervical dilation, the median 
time to progress 1 cm cervical dilation was similar in induced and 
spontaneous labor (Figure 10) (280). 
 
 
Figure 10. Average labor curves stratified by parity and type of labor onset. Reprinted from 
Harper et al. with permission of the publisher (280). 
 
 
Recent guidelines for assessing progress of labor substantially differ from 
those initially described by Friedman in 1954 (281). Previous studies have 
concluded that for most nulliparous women undergoing IOL, the active phase 
of labor occurs only at 6 cm of cervical dilation, and between 6 and 18 hours 
of the latent phase (282-284). A retrospective cohort study demonstrated 
that the transition from latent to active labor occurred at 4 cm of cervical 
dilation with IOL by misoprostol, and at 6 cm of cervical dilation with IOL by 
FC (Figure 11) (285). The initial dilation from 1 to 4 cm was more rapid with 
use of FC (3.4 h vs. 5.6 h; p<0.01), but the dilation from 4 to 10 cm was faster 
with the use of misoprostol (6.3 h vs. 3.6 h; p<0.01). However, the total 
duration of labor was similar between women induced with FC and women 





Figure 11. Average labor curves for women induced with misoprostol (red line) or FC (blue 
line). Reprinted from Tuuli et al. 2013 with permission of the publisher (285). 
 
 
Several studies have demonstrated that a substantial proportion of women 
will transit into active labor and deliver vaginally if induction is continued in 
the setting of ruptured membranes and oxytocin administration for 12−18 
hours (282, 286). A recent retrospective cohort study on 228 562 deliveries 
concluded that before considering an induction failed, at least 12 hours of 
oxytocin administration with ruptured membranes are reasonable in 
nulliparous women, and 15 hours in multiparous women (284). The study 
also demonstrated that the amount of nulliparous women entering active 
labor increased to over 60% between 6 and 18 hours of the latent phase 
(284). Nulliparous women remaining in the latent phase for ≥ 12 hours had 
increased rates of chorionamnionitis (12.1% vs. 4.1%; p<0.001), postpartum 
endometritis (3.6% vs. 1.3%; p<0.01), and NICU admission (8.7% vs. 6.3%: 
p<0.05) compared to nulliparous women who had transited into the active 
phase of labor earlier (284). Similar patterns were seen for multiparous 
women at 15 hours of the latent phase (284). Furthermore, postpartum 
hemorrhage was more common in women with a prolonged latent phase of 
≥15 hours compared to those with a shorter latent phase of labor (14.8% vs. 
3.1%; p<0.001 for nulliparous women, and 6.5% vs. 4%; p<0.05 for 








MATERNAL SATISFACTION WITH LABOR INDUCTION 
 
Maternal satisfaction is associated with several health, social, and care 
factors, such as young age, no physical disability, positive reaction to 
pregnancy, no antenatal depression, fewer worries about pregnancy and 
labor, and access to information about choices of care (37). A secondary 
analysis of surveys regarding care during labor showed that women 
undergoing IOL were less likely to be satisfied with their care and labor (38). 
Women also reported feelings of neglect, insufficient pain relief, plans not 
being followed, wasted effort, and disappointment if their IOL was 
unsuccessful (38). A small interview study demonstrated that the feelings of 
women undergoing IOL vary considerably (287). Some women are concerned 
about the impact of IOL on the fetus, whereas some express anxiety over the 
effect on themselves and a loss of a natural birth (287). Women’s experiences 
of IOL with oral misoprostol and FC are similar (221). Cervical ripening in an 
outpatient setting may increase maternal satisfaction (288, 289). The 
progress of IOL and labor is shown to be the most important factor affecting 
overall maternal satisfaction (290). Although most studies on maternal 
satisfaction are small and biased, the results highlight the aspects of care 




ECONOMIC IMPLICATIONS OF LABOR INDUCTION 
HEALTH CARE COSTS RELATED TO LABOR INDUCTION 
 
Maternal, neonatal, and treatment related factors influence the total costs of 
IOL. Moving cervical ripening from inpatient to outpatient setting may 
decrease the use of health care resources and costs. An American cost-
minimization analysis on 76 women undergoing either outpatient or 
inpatient cervical ripening by PGE2 preparation reported that outpatients 
incurred significantly less costs (mean $3835 vs. $5049) and time (74.4 h vs. 
33.1 h) compared to inpatients (36). In an Australian study, the total health-
care costs were not lower with outpatient IOL by FC compared to inpatient 
IOL by PG (291). However, outpatients experienced fewer inpatient hours 
and costs prior to delivery (291). According to a recent European cohort 
study, the mean total cost of IOL in a woman with unfavorable cervix is 
approximately 3600€, with maternal and neonatal outcomes, mode of 
delivery, professional fees, epidural analgesia, maternal stay, consumables, 
and drugs taken into account (292). The highest costs of labor induction were 
 
48 
associated with an unfavorable cervix and hypertension as the indication for 
IOL (292). 
 
CS following IOL was significantly more expensive than vaginal delivery 
following IOL (292). However, there is evidence that inducing labor in 
women with complications is associated with lower health-care costs than 
expectant management (34, 35). In Finland, the rate of IOL has increased by 
over 50% during the past decade. During this period the rate of CS has 
remained stable, and the number of vaginal deliveries following IOL has 
increased (4) (Figure 12). 
 
 
Figure 12. The rates of all planned and emergency cesarean deliveries, IOL, and vaginal 
deliveries following labor induction in Finland during 2006−2015 (4) (submitted). 
 
 
Different induction methods have different direct and indirect costs, 
including retail price, frequency of fetal monitoring needed, risk of 
complications, CS, and admissions to NICU. Unfortunately, little evidence on 
the total costs related to specific methods of IOL is available. A recent meta-
analysis and cost-effectiveness analysis found, with considerable uncertainty 
in estimates, that titrated low dose solution of misoprostol appeared the most 
cost-effective method (293). Misoprostol solution was used in early clinical 
studies due to unavailability of low dose tablets, and the pharmacokinetics 
compared to tablets is unclear. Also, buccal or sublingual misoprostol, 
intravenous oxytocin with amniotomy, and vaginal misoprostol were deemed 
cost-effective (293). When comparing the efficacy and cost-effectiveness of 
single and double balloon catheters, FC is the method of choice based on its 
significantly lower cost, association with lower rates of adverse outcomes, 
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and improved pain scores (20, 176). Two economic evaluation models have 
suggested that IOL with misoprostol vaginal insert may lead to a reduction in 
resource use and hospital stay, leading to lower total costs (294, 295). 
OPTIMIZING DAYTIME DELIVERY 
 
Several studies suggest that in addition to being more cost-effective, daytime 
deliveries have better outcomes compared to deliveries at night (296-298). A 
similar effect has been demonstrated between working days and weekends 
(298). Different starting times of IOL may be beneficial when optimizing 
daytime deliveries, depending on parity and the method of IOL. No strong 
evidence exists that timing of the first dose of misoprostol tablets or 
dinoprostone affects the risk of nighttime delivery (299, 300). According to a 
recent clinical trial, optimal starting time for achieving daytime delivery in 
use of vaginal misoprostol insert appears to be 19:00 for nulliparous women, 
and 23:00 for multiparous women (301). A retrospective study on 732 
women suggests that the risk of nighttime delivery in nulliparous women is 
lower if FC is inserted in the evening after 18:00 (300). The recent Cochrane 
review concluded that no evidence on the superiority of morning versus 
evening IOL with intravenous oxytocin exists (302). However, a recent 
retrospective cohort study demonstrated that morning induction with 
























AIMS OF THE STUDY 
The present study was carried out to investigate the safety and efficacy of 
labor induction by FC. The specific aims were: 
 
 
1. To evaluate delivery outcomes in prolonged and post-term 
pregnancies induced by FC compared to women with spontaneous 
onset of labor. 
 
2. To study labor outcomes in nulliparous women undergoing IOL by 
FC, and to assess risk factors for cesarean delivery and maternal 
and neonatal infections. 
 
3. To compare FC and oral misoprostol for IOL in women with term 
PROM. 
 
4. To investigate outpatient IOL by FC, and to compare labor 
outcomes and preferences of inpatients and outpatients. 
 
5. To examine cervical biomarkers including IGFBP-1, phIGFBP-1, 
MMPs -2, -8, -9, and their tissue inhibitors (TIMP) -1 and -2 
during FC induced cervical ripening in nulliparous women, and to 






















SUBJECTS AND METHODS 
SUBJECTS 
 
The study was conducted in the Department of Obstetrics and Gynecology of 
Helsinki University Hospital between 2011 and 2015. The Department of 
Obstetrics and Gynecology of Helsinki University Hospital includes three 
individual hospitals: the Women’s Hospital, the Maternity Hospital, and 
Jorvi Hospital. Study III was carried out in collaboration with the 
Department of Obstetrics and Gynecology in both Oulu University Hospital 
and Tampere University Hospital. The study protocols were approved by the 
Helsinki and Uusimaa Hospital District Ethics Committee for Obstetrics and 
Gynecology, Pediatrics, And Psychiatry (No. 30/13/03/03/2012 and No. 
268/13/03/03/2012). Approval to carry out the study was granted by the 
Hospital District of Helsinki and Uusimaa (§7, §14, §20, and §41). 
 
The total study population consisted of 1693 women. The characteristics of 
studies I–V are summarized in Table 6. Written informed consent was 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6 and figure 13 describe the characteristics of study I. The data were 





Figure 13. Flow chart of the women ≥ 41 ⁵ weeks of gestation undergoing IOL by FC or 
















The characteristics of study II are described in Table 6 and Figure 14. The 

























Table 6 and Figure 15 describe the characteristics of the multicenter study 
III. The randomization was done by sealed envelopes in a 1:1 ratio. This study 
was open-label because the nature of the intervention made masking 
impossible. After 2.5 years of the study, an interim analysis was performed. 
Since no differences between the groups were found, and patient enrollment 




Figure 15. Flow chart of the women randomized to IOL by FC or misoprostol after PROM at 












Study IV characteristics are described in table 6 and Figure 16. Prior to IOL, 
all women underwent a cardiotocography (CTG) and an ultrasonographic 
assessment of fetal biophysical profile including amniotic fluid volume. The 
women with reassuring test results were then offered an option for 









Table 6 describes the characteristics of study V. None of the participants had 
regular contractions or any evidence of rupture of membranes at the time of 
enrollment. One woman ruptured the membranes during insertion of the FC, 







DATA COLLECTION FROM MEDICAL RECORDS 
 
Clinical data on the study populations were collected from hospital patient 
records (I−V), by interviews (III−V), and from statistical survey form by the 
National Institute for Health and Welfare assessing maternal height, weight, 
BMI, smoking, assisted reproductive in vitro fertilization (IVF) treatment, 
and history of previous pregnancies (I−V). Data on IOL, and delivery and 
neonatal outcomes were collected from the hospital patient records (I−V). 
Maternal characteristics (I−V) 
Maternal characteristics, and delivery and neonatal outcome parameters 
evaluated in studies I−V are presented in Table 7. 
Table 7. Maternal characteristics and labor outcome parameters of studies I−V 
 
Maternal characteristics Delivery and neonatal outcomes 
Maternal age  Mode of delivery 
Height Indication for CS 
Weight Prophylactic antibiotic use 
Pre-pregnancy BMI  Oxytocin administration 
IVF  Epidural and/or spinal analgesia 
Smoking Fetal scalp blood sampling 
Pregestational diabetes  Meconium-stained amniotic fluid 
Gestational diabetes Uterine hyperstimulation 
Insulin dependent gestational diabetes Fetal tachycardia 
Gestational age  Placental retention 
PROM Sphincter injury 
Bishop score  Postpartum hemorrhage  
Indication for labor induction Fever ≥38°C during labor 
History of previous CS Maternal intrapartum infection 
Maternal postpartum infection 
 Birth weight 
 Apgar score  
 
Umbilical artery blood pH and base excess 
(BE) values 
 Gender 
 Neonatal infection 
 Admission to neonatal care unit 
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In all studies included in this thesis, BMI 30 kg/m² was defined as a cut-off 
for obesity. GDM was diagnosed by a 2-hour oral glucose tolerance test 
during the first or the second trimester, and 5.3, 10.0, and 8.6 mmol/L were 
used for 0-, 1-, and 2-hour cut-off values (104). Women who were diagnosed 
with GDM but had normoglycemia and normal fetal growth while on dietary 
care, were analyzed as uncomplicated pregnancies in studies I and IV. 
Women smoking during any trimester were defined as smokers. 
 
The type and length of pregnancy were based on the results of first trimester 
ultrasound screening in all cases. Prolonged pregnancy was defined as 
gestational age ≥ 41⁺⁵ weeks, and post-term pregnancy as gestational age ≥ 
42⁺⁰ weeks. All women were induced at the latest by 42⁺¹ gestational weeks if 
spontaneous labor had not commenced. 
 
Cervical ripeness was defined by the Bishop score, with Bishop score < 6 
indicating an unripe cervix, and Bishop score ≥ 6 representing a ripe cervix. 
All women had a Bishop score < 6 at the start of IOL. PROM was diagnosed 
by clinical examination or by a positive rapid vaginal dipstick test 
(ActimProm, Medix Biochemica, Espoo, Finland). 
 
The main indications for labor induction followed the hierarchy of PROM, 
post-term pregnancy, hypertensive disorders, pregestational or gestational 
diabetes, intrahepatic cholestasis of pregnancy, and other indications. When 
there was more than one indication for CS, the primary indication was 
categorized by using the following hierarchy: fetal distress, infection, failure 
to progress, failed induction, and other indications. 
Delivery outcome parameters (I−V) 
The time intervals (hours) describing different phases of the induced 
deliveries were collected from hospital records. The duration of the FC 
retention was defined as the interval from FC insertion to its expulsion or 
removal. The induction to delivery interval was defined as the time from 
insertion of FC (I−V) or administration of the first misoprostol dose (III) to 
delivery. The first stage of labor was defined as the interval from regular 
contractions to start of pushing (303). The second stage of labor was defined 
as the interval from start of pushing to delivery (303). 
 
Regular contractions were defined as contractions every 3−5 minutes with 
cervical dilation of a minimum of 3 cm. Uterine hyperstimulation was 
defined as > 5 contractions in a 10-minute period, or a contraction lasting 
longer than 3 minutes in a combination with fetal heart rate changes (III). 
Failed induction was diagnosed after ruptured membranes and 6−12 hours of 
oxytocin administration without cervical change (304). Labor arrest in the 
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first stage of labor was defined as failure to progress despite ruptured 
membranes and a minimum of 4 hours of adequate uterine activity without 
cervical change (304). 
Maternal and neonatal outcomes (I−V) 
Maternal infections were categorized as intrapartum (during labor) and 
postpartum (from delivery to discharge). The criteria for intrapartum 
infection (I−II, IV−V) were maternal fever (≥ 38°C) during labor, fetal 
tachycardia (≥ 160 bpm), uterine tenderness, purulent amniotic fluid or 
vaginal discharge, total white cell count > 20 E9/L, and histopathological 
diagnosis of chorionamnionitis if clinically indicated. At least two of these 
criteria had to be met in combination with administration of antibiotics. For 
study III, maternal fever ≥ 38°C alone was used as a definition for 
intrapartum infection. Postpartum infections included endometritis, wound 
infections, and puerperal fever of unknown origin (I−V). Postpartum 
endometritis was defined as uterine tenderness, purulent vaginal discharge, 
total white cell count > 10 e9/L. The infections were categorized according to 
the following hierarchy: intrapartum infection, postpartum endometritis, and 
other postpartum infections. The woman was diagnosed with either 
intrapartum infection or postpartum endometritis, while intrapartum 
infection and other postpartum infections could occur in the same woman. 
 
Neonatal infections (I−II, IV) were categorized as blood culture positive 
sepsis, clinical sepsis, and suspected sepsis. Neonatal clinical sepsis was 
defined as a blood culture negative infection with symptoms and signs 
consistent with sepsis (including respiratory distress, apnea, tachycardia, 
poor perfusion, low blood pressure, fever, hypo- or hyperglycemia, 
irritability, feeding problems, lethargy, and convulsions), abnormal blood 
test values (such as elevated levels of C-reactive protein, leukocytosis or 
leukopenia, increased neutrophil precursor counts, and thrombocytopenia), 
and a positive response to a minimum of a 5-day antibiotic treatment. The 
cases defined as suspected sepsis had to have at least one symptom and one 
abnormal blood test result, and a positive response to antibiotic treatment. 
During data collection, the diagnoses of neonatal infections were confirmed 
and categorized from patient records by a neonatologist (I−II, IV). For study 
III, any clinical suspicion of neonatal infection was used as the definition of 
neonatal infection. 
Maternal satisfaction with induction of labor 
Maternal satisfaction with outpatient IOL experience was measured after 
delivery using a Likert scale questionnaire with ratings 1−5 (very negative – 
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negative – no opinion – positive – very positive) (Figure 17) (IV) (305). The 
questionnaire was attached to the patient records when the decision on 
outpatient IOL was made. The women filled in the questionnaires during 
their stay in the postpartum ward and returned the completed forms to the 
mail boxes of the ward. The correlation of maternal satisfaction and labor 
outcome parameters was not included in the analysis. 
 
Figure 17. Questionnaire used to measure maternal satisfaction during postpartum care in 
women who underwent outpatient IOL by FC (translated from Finnish to English) (IV). 
MANAGEMENT OF LABOR INDUCTION 
Cervical ripening by Foley catheter in inpatient care (I−V) 
When mechanical cervical ripening was used for IOL, a single balloon FC 
(Rusch 2-way Foley Couvelaire tip, catheter size 22 Ch, Teleflex Medical, 
Athlone, Ireland) was inserted through the cervix towards the space between 
the amniotic membrane and lower uterine segment blindly during vaginal 
examination, or by direct visualization during a speculum examination. The 
balloon reservoir was inflated with 40−50 ml of saline and retracted so that it 
rested on the internal os. Transvaginal ultrasound was performed to assure 
balloon placement if needed. Light traction was applied, and the catheter was 
taped on the inner aspect of the thigh. A midwife monitored for balloon 
expulsion every 2−4 hours, and light traction was reapplied if necessary. The 
FC was retained for a maximum of 24 hours (I−II, IV−V), or in case of PROM 
for 8 hours with prophylactic antibiotic treatment (III). If spontaneous 
expulsion of the balloon did not occur within 24 hours, the FC was removed. 
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After spontaneous expulsion or removal of FC, the cervix was assessed. If the 
cervix was ripened to a Bishop score of ≥ 6, amniotomy was performed and 
continuous fetal monitoring was started. The timing of amniotomy after FC 
expulsion or removal varied from immediate to 12 hours, depending on the 
time of expulsion, inpatient or outpatient setting of IOL, and delivery unit 
capacity. If the cervix remained unripe with Bishop score < 6 after FC 
expulsion or removal, further management of cervical ripening was 
considered by the obstetrician in charge. 
Cervical ripening by Foley catheter in outpatient care (IV) 
The idea of a procedure for outpatient IOL was introduced to obstetricians 
and midwives by presentations and staff meetings. Written information and 
practical training on various clinical situations with outpatient FC induction 
were offered. In study IV, all women with an uncomplicated pregnancy, 
reassuring cardiotocography, and a normal fetal biophysical profile were 
offered an option for outpatient IOL. All procedures for FC induction were 
similar to those described in the chapter Cervical ripening by Foley catheter 
in inpatient care (page 52). Parturients who chose outpatient IOL were 
discharged after receiving counseling regarding the IOL management, 
discomfort, pain relief, and probability of balloon expulsion, and after 
signing an informed consent form. They were advised to check for balloon 
expulsion by pulling the catheter, and to contact the delivery unit after 
balloon expulsion. If the balloon was expulsed during the nighttime, the 
outpatients were asked to return to the delivery unit the following morning, 
unless they had any concerns or PROM occurred. In addition, oral and 
written instructions with 24-hour contact information were provided, and 
the women were advised to immediately contact the delivery unit in case of 
bleeding, severe pain, fever, ruptured membranes, or decreased fetal 
movements. Non-expulsed FCs were removed after a maximum of 24 hours, 
similarly to inpatient procedure. 
Cervical ripening by misoprostol (III) 
Synthetic 100 μg misoprostol tablets (Cytotec®, Piramal Healthcare UK 
Limited, Northumberland, England) divided into two (50 μg each) were 
administered orally every 4 hours for cervical ripening. Cardiotocography 
and uterine contractions were recorded for 30 minutes prior to misoprostol 
administration, for 60 minutes after the medication, and in case of regular 
contractions. If regular contractions did not occur following three doses of 
misoprostol, oral dose was increased to 100 μg or induction was continued by 
vaginal administration of 25−50 μg doses every 4 hours. 
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Oxytocin induction and augmentation (I−V) 
After reaching Bishop score ≥ 6, oxytocin induction was started in the 
absence of regular contractions. The timing of oxytocin induction was 
initiated by local hospital policy, delivery unit capacity, and the preference of 
the managing obstetrician, varying between 2 and 24 hours after 
spontaneous or artificial rupture of membranes. In cases with prior 
misoprostol use, administration of oxytocin was started at the earliest 4 
hours after the last dose of misoprostol. Oxytocin 5 IU (8.3 μg) (Syntocinon; 
Novartis, Copenhagen, Denmark) was diluted in 500 ml isotonic saline or in 
5% glucose infusion. The administration was initiated at 15 ml/h, and 
increased by 5 ml every 15 minutes, or by 10 ml every 30 minutes, until 
regular contractions were achieved, or until the maximum dose of 90 ml/h 
for 6 hours was reached. 
 
Oxytocin augmentation during labor, initiated by a midwife or an 
obstetrician, was routinely used in studies I−V. If uterine activity was 
insufficient (less than three contractions in a 10-minute period, or < 200 
Montevideo units according to intrauterine pressure catheter monitor), 
oxytocin was continuously infused until 3−4 contractions occurred per 10 
minutes, or ≥ 200 Montevideo units were achieved, or the progression of 
labor was deemed adequate. Intrauterine pressure catheter was used per 
obstetrician preference. 
Group B streptococcus screening and antibiotic prophylaxis (I−V) 
GBS (Streptococcus agalactiae) was tested by a culture from vaginal and 
perianal specimen collected at prenatal visit 4 weeks prior to delivery, or at 
admission. During studies I, II, and IV, a risk-group based strategy for GBS 
screening was used. In study III, all women with FC induction after term 
PROM were tested for GBS. In study V, a rapid qualitative in vitro GBS test 
(Xpert® GBS, Cepheid, Sunnyvale, California, USA) was performed in all 
cases after collecting the biomarker samples. 
 
Administration of antibiotics to GBS-positive women was started after 18 
hours from PROM or amniotomy, or at the start of regular contractions (I−II, 
IV). In study III, all women received prophylactic antibiotics at the initiation 
of IOL by FC or misoprostol. In study V, antibiotic prophylaxis was in case of 
positive GBS result started immediately following rupture of membranes. 
Benzylpenicillin was routinely used for antibiotic prophylaxis with the first 
dose of 4 million units intravenously, followed by 2.5 million units every 4 
hours until delivery. In case of a penicillin allergy, clindamycin 900 mg was 
administered every 8 hours intravenously. In study III, intravenous 
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cefuroxime 1.5 g, or in case of allergy clindamycin 900 mg every 8 hours, was 
used for all women. 
CERVICAL BIOMARKER SAMPLES AND ASSAYS (V) 
 
For the cervical biomarker analyses in study V, 4 cervical swab samples were 
collected prior to insertion and after expulsion of the FC, with a maximum 
delay of 10 minutes before insertion and after expulsion. The samples were 
obtained by rotating a sterile swab in the inner walls of the cervical canal for 
15 seconds during speculum examination. The swabs were then each swirled 
in their respective extraction solution for 15 seconds. The sample solutions 
were frozen and stored at −20°C until the analysis of IGFBP-1, phIGFBP-1, 
MMP-2, MMP-8, MMP-9, TIMP-1, and TIMP-2 concentrations. The same 
physician examined all women and collected all samples. All samples were 
analyzed in the same laboratory (Medix Biochemica, Espoo, Finland), which 
was blinded to the outcome of labor induction. 
IGFBP-1 and phIGFBP-1 concentrations 
Concentrations of cervical IGFBP-1 and phIGFBP-1 were quantitated by 
using monoclonal antibodies in two immunoenzymometric assays (IEMA) 
(Medix Biochemica, Espoo, Finland). The IGFBP-1 assay employs 
monoclonal antibody 6305, and detects the non-phosphorylated and less 
phosphorylated isoforms of IGFBP-1 (306). The phIGFBP-1 assay employs 
monoclonal antibody 6303, and recognizes the highly phosphorylated forms 
of IGFBP-1 (307). Analyses were performed according to the manufacturer’s 
instructions (Medix Biochemica, Espoo, Finland). All samples were 
measured in duplicate, and the two assays were performed in parallel for 
each set of samples. The results were read from the standard curve, and the 
mean value of the results was reported. The detection limit of the assay was 
0.3 μg/L, and the intra- and inter-assay variations were 4.6% and 6.4%, 
respectively. One plate allows the determination of 40 samples in duplicate, 
and a standard curve for each plate was utilized. A comparison of standard 
curves for the plates used during the study period of December 2014 and 
June 2015 ensured that no variation of the results occurred. 
MMP-8 concentrations 
MMP-8 concentration was measured with a solid-phase IEMA (MMP-8 
IEMA, Medix Biochemica, Espoo, Finland) (308). The MMP-8 IEMA is a 
quantitative enzyme immunoassay using two monoclonal antibodies, 8706 
and 8708, against human MMP-8 (Medix Biochemica, Espoo, Finland). 
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Microplate wells are coated with one monoclonal antibody against MMP-8, 
and the other antibody is conjugated to horseradish peroxidase, forming the 
enzyme conjugate used to detect the presence of MMP-8. Analyses were 
performed according to the manufacturer’s instructions (Medix Biochemica, 
Espoo, Finland), and the solution absorbance in the wells was measured at 
414 nm with a microplate reader (Multiskan, Thermo Fisher Scientific, 
Vantaa, Finland). All analyses were performed in duplicate, and the mean 
absorbance value for each duplicate set was read from a standard curve for 
MMP-8. One plate allows the determination of 40 samples in duplicate, and 
a standard curve for each plate was used. A comparison of standard curves 
for the plates used during the study period of December 2014 and June 2015 
ensured that no variation of the results occurred. The results were reported 
as the mean value of MMP-8. The intra-assay and inter-assay coefficients of 
variation for MMP-8 were both lower than 6%, and the detection limit used 
for the assay was 0.4 ng/ml. 
MMP-2, MMP-9, TIMP-1, and TIMP-2 concentrations  
MMP-2, MMP-9, TIMP-1, and TIMP-2 analyses were carried out using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits 
(Biotrak ELISA Systems; GE Healthcare Life Sciences, Chicago, Illinois, USA 
for MMP-2 and TIMP-1, and Quantikine ELISA Kit; R&D Systems, 
Minneapolis, Minnesota, USA for MMP-9 and TIMP-2). All experimental 
procedures were performed according to manufacturer’s instructions. All 
samples were measured in duplicate, and the assays were performed in 
parallel for each set of samples. The results were read from the standard 
curve, and the mean value of the results was reported. The intra- and inter-
assay coefficients of variation for MMP-2 were < 7% and < 13%, for MMP-9 
<3% and <8%, for TIMP-1 <12% and <6%, and for TIMP-2 <7% and <8%, 
respectively. The detection limits used were 0.37 ng/ml for MMP-1, 0.16 
ng/ml for MMP-9, 1.25 ng/ml for TIMP-1, and 0.064 ng/ml for TIMP-2. The 
balance between the MMP-8 and TIMP-1 quantities was estimated on the 
basis of the molar ratio. 
STATISTICAL ANALYSES (I−V) 
 
The data analyses in this thesis were performed by using the Statistical 
Package for Social Sciences (SPSS) PASW Statistics for Windows, Version 
18.0 (SPSS Inc., Chicago, IL, USA) (studies I, II), IBM SPSS Statistics for 
Windows, Version 20.0 (Armonk, NY, USA) (studies III, IV), and IBM SPSS 
Statistics for Windows, Version 22.0 (study V). A p-value less than 0.05 was 
considered statistically significant. A post-hoc power analysis was performed 
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by simulations using R software (II). In study III, the sample size was 
determined by power analysis. 
 
Categorical variables were compared by Pearson’s Chi-square test or Fisher’s 
exact test when appropriate (I−V). Unpaired comparisons of continuous 
variables were carried out by Student’s t-test if the data were normally 
distributed, and by Mann–Whitney U test in case the data did not follow a 
normal distribution (I−V). Labor outcomes of nulliparous and multiparous 
women were analyzed separately in studies I and IV. The Kaplan-Meier 
survival curve was used for analysis of induction to delivery interval (III). 
Univariate logistic regression analysis, represented by ORs with 95% CIs, was 
performed to estimate the RR for CS (studies I, II). Multivariate logistic 
regression analyses were performed to control for possible confounding 
factors (Table 8), and for calculating adjusted ORs and their 95% CIs for CS 
and maternal and neonatal infections (II, IV). Correlations between the 
cervical biomarker concentrations and labor outcomes were analyzed by 
using Pearson’s correlation coefficient (V). 
 
Table 8. Maternal and delivery related confounding factors used in the multivariate 
regression analyses in studies II and IV assessing risk factors for CS and maternal and 
neonatal infections (II, IV) 
 
Risk factor Study II Study IV 
Maternal age ≥37 years x x 
IVF x x 
Smoking x x 
Nulliparity x 
History of previous CS x 
BMI ≥30 x x 
GDM (insulin and non-insulin dependent) x x 
Hypertensive disorder x 
Post-term pregnancy (≥42 weeks) x 
Outpatient setting x 
Bishop score ≤3 at the start of IOL x x 
Cervical effacement >2 cm at the time of amniotomy x 
Cervical dilation ≤3 cm at the time of amniotomy  x 
Amniotomy in ≤2 h or >2 h after balloon expulsion  x 
Amniotomy ≤12 h or >12 h after balloon expulsion x 
Oxytocin induction x x 
Oxytocin administration in ≤3 h or >3 h after amniotomy x 
Oxytocin administration in ≤12 h or > 2 h after amniotomy  x 
Early epidural analgesia (prior to regular contractions or at cervical 




FOLEY CATHETER INDUCTION IN PROLONGED AND 
POST-TERM PREGNANCIES (I) 
 
The clinical characteristics of the women with prolonged and post-term 
pregnancies are shown in Table 9. The women undergoing IOL were more 
often nulliparous and post-term, and more often had a Bishop score ≤ 3 at 
41+5 gestational weeks (Table 9). 
 
 










Maternal age ≥35 years 21 (65) 28 (70) 0.07 
Nulliparous 81 (244) 50 (126) <0.001 
BMI ≥30 11 (34) 9 (22) 0.28 
GDM 9 (27) 9 (22) 0.96 
Bishop score ≤3 at 41+5 
weeks 49 (148) 15 (38) <0.001 
Gestational age 41.8 [0.14] 41.8 [0.13] 0.05 
Post-term ( ≥42+0) 65 (197) 26 (65) <0.001 
Data presented as % (n) or mean [SD]. SD = standard deviation. 
 
 
Only 10% of the women who presented with an unfavorable cervix at 41+5 
gestational weeks had an improved Bishop score ≥ 6 during expectant 
management from 41+5 to 42+1 gestational weeks. The nulliparous women 
with Bishop score ≤ 3 more often needed oxytocin induction after FC 
expulsion (50% vs. 38%; p=0.01), and more often failed to achieve vaginal 
delivery following IOL (44% vs. 31%; p=0.04) compared to nulliparous 
women with Bishop score > 3. In contrast, most multiparous women 







MATERNAL DELIVERY OUTCOMES 
 
The median (range) time the FC was retained was 9(0.3−30) h in nulliparous 
women, and 5(0.3−24) h in multiparous women (I). The median (range) time 
from the start of regular contractions to vaginal delivery was shorter in 
induced labor than in spontaneous labor (11[3−34] h vs. 13[3−35] h; 
p=0.004). Maternal delivery outcomes are presented in Table 10. 
 
Table 10. Maternal delivery outcomes of nulliparous and multiparous women with FC 
induced and spontaneous labors at 41+5 to 42+1 gestational weeks (n=553) (I) 
 









CS 37 (91) 9 (11) <0.001 3 (2) 1 (1) 0.20 
Fetal distress 16 (38) 5 (6) 0.42 −  −  − 
Infection 3 (7) −  0.34 −  1 (1) − 
Failure to progress 19 (46) 4 (5) 0.29 3 (2) −  − 
Vacuum extraction 18 (45) 24 (30) 0.55 7 (4) 2 (3) 0.21 
PPH ≥1000 ml       
Vaginal delivery 9 (21) 10 (13) 0.56 7 (4) 8 (10) 0.80 
CS 14 (33) 2 (3) 0.93 2 (1) −  − 
Intrapartum infection 6 (15) 2 (3) 0.13 2 (1) 1 (1) 0.54 
Postpartum infection 4 (9) 2 (2) 0.26 2 (1) −  − 
Placental retention 3 (8) 3 (4) 0.49 3 (2) 3 (4) 0.93 
Sphincter injury 0.4 (1) 4 (5) 0.97 −  1 (1) − 
Laparotomy 1 (2) −  − −  −   
Hysterectomy −  −  − −  −  − 
Data presented as % (n). PPH = Postpartum hemorrhage. 
 
 
The CS rate of nulliparous women was higher in induced labor compared to 
spontaneous labor (37% vs. 9%; p<0.001) (Figure 18). In multiparous 
women, this difference was not seen (Figure 18). Nulliparous women had an 




Figure 18. CS rates following IOL and spontaneous onset of labor in prolonged and post-




The maternal intrapartum infection rates were not significantly different 
between induced and spontaneous labors (6% vs. 2%; p=0.13 in nulliparas, 
and 2% vs. 1%; p=0.54 in multiparas). The rates of postpartum infection or 
postpartum hemorrhage were not significantly different between the groups 
(Table 10). Two laparotomies were performed for women who delivered by 
CS following IOL; one due to an infection and the other due to postpartum 
hemorrhage (Table 10). 
NEONATAL OUTCOMES 
 
The neonatal outcomes are summarized in Table 11. The umbilical cord blood 
gas values, Apgar scores, and neonatal care admission rates were not 
significantly different between the groups of induced and spontaneous labor 
(Table 11). Neonatal infection was more often suspected following IOL than 
spontaneous labor in nulliparous women (8% vs. 2%; p=0.04), but the rates 
of clinical neonatal sepsis were similar between the groups (Table 11). In 
multiparous women no difference between IOL and spontaneous onset of 
labor was detected (3% vs. 2%; p=0.60) (Table 11). No cases of blood culture 









Table 11. Neonatal outcomes in FC induced and spontaneous deliveries at 41+5 to 42+1 
weeks (n=553) (I) 
 









Apgar score 1 min <7 9 (22) 7 (9) 0.50 5 (3) 4 (5) 0.75 
Apgar score 5 min <7 3 (8) 1 (1) 0.23 −  1 (1) 0.53 
Umbilical artery pH 
<7.05¹ 2 (5) 4 (5) 0.32 5 (3) 1 (1) 0.09 
Umbilical artery BE 
≤−12.0¹ 3 (7) 5 (6) 0.40 2 (1) 1 (1) 0.52 
Neonatal infection 8 (19) 2 (3) 0.04 3 (2) 2 (2) 0.60 
       Suspected sepsis 5 (13) 2 (2) − 3 (2) 1 (1) − 
       Clinical sepsis 2 (5) 1 (1) − −  1 (1) − 
       Unknown origin 0.4 (1) −  − −  −  − 
Admission to NICU 12 (30) 10 (12) 0.45 −  1 (1) 0.49 
Admission to neonatal 
ward 3 (7) 2 (2) 0.43 3 (2) 4 (5) 0.83 


























LABOR INDUCTION BY FOLEY CATHETER IN 
NULLIPAROUS WOMEN WITH TERM PREGNANCY (II) 
 
Table 12 shows the clinical characteristics of the nulliparous women 
undergoing labor induction by FC. 
 
Table 12. Clinical characteristics of the nulliparous women undergoing IOL by FC (n=432) 
(II) 
 
Clinical characteristic % (n) 
Maternal age ≥35 years 20 (86) 
BMI ≥30 15 (64) 
GDM 19 (81) 
Bishop score ≤3  48 (209) 
Gestational age 41.0 [1.4] 
Post-term ( ≥42+0) 17 (73) 
Indication for IOL   
Post-term pregnancy 62 (266) 
Hypertensive disorders 13 (56) 
Gestational diabetes 7 (29) 
FGR 5 (23) 
Oligohydramnion 4 (19) 
Intrahepatic cholestasis 4 (16) 
Other* 5 (23) 
Data presented as % (n) or mean [SD]. SD = standard deviation. 
*Other: decreased fetal movements n=8, large for gestational age fetus n=4, fetal disease (cardiac 
malformation, Catch-22) n=2, maternal disease (back pain, heart transplantation, difficulty urinating, 
ulcerative colitis) n=3, pregestational diabetes type 1, n=3, psychosocial reasons n=3. 
 
CHARACTERISTICS OF LABOR INDUCTION 
 
Spontaneous expulsion of the FC occurred in 90% of the women 
(unpublished data). Prior to expulsion of the FC, spontaneous rupture of 
membranes occurred in 6% of the women, and in 11% contractions started 
spontaneously. Following expulsion of the FC, amniotomy was performed in 
88% of the cases, and spontaneous rupture of membranes occurred in 11% of 
the women. Altogether, 12% of the women had an unripe cervix (Bishop score 
< 6) after FC expulsion and underwent subsequent cervical ripening by 
misoprostol. Of the women undergoing IOL by FC, 42% needed oxytocin for 
inducing contractions, while 57% started spontaneous contractions. Early 
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epidural or spinal analgesia was started prior to regular contractions or 
cervical dilation of 3 cm in 3% of the women. 
 
The duration of FC induced labor in nulliparous women resulting in vaginal 
delivery is presented in Figure 19 (unpublished data). The median induction 
to delivery interval was 29.5 (interquartile range 20–36, 






Figure 19. Induction to vaginal delivery intervals in nulliparous women undergoing IOL by 




The delivery outcomes are shown in Table 13. The CS rate in nulliparous 
women undergoing IOL by FC was 39%, and 46% in the women who needed 
subsequent use of misoprostol after FC. The most common indication for CS 
was failure to progress; failed induction 7% (n=32), and labor arrest 12% 











Table 13. Delivery outcomes of nulliparous women undergoing IOL by FC (n=432) 
 
Delivery outcome % (n) 
Cesarean section 39 (169) 
Fetal distress 15 (63) 
Infection 3 (12) 
Failure to progress 20 (85) 
Other¹ 2 (9) 
Vacuum extraction 16 (71) 
Postpartum hemorrhage ≥1000 ml 21 (92) 
Suspected intrapartum infection 6 (27) 
Postpartum infection 4 (17) 
Placental retention 3 (14) 
Grade III perineal tear 1 (3) 
Laparotomy 1 (5) 
Hysterectomy − − 
Apgar score 1 min <7 9 (40) 
Apgar score 5 min <7 4 (17)2 
Umbilical artery pH <7.05 2 (10)³ 
Umbilical artery BE ≤−12.0 2 (9)³ 
Neonatal infection 9 (38) 
Suspected sepsis 5 (21) 
Clinical sepsis 3 (12) 
Unspecified infection 1 (5) 
Admission to NICU 2 (9) 
Admission to neonatal ward 16 (67) 
Data presented as % (n). 1Other: bleeding n=1, preeclampsia n=3, umbilical cord prolapse n=1, 
maternal exhaustion n=2, failed vaginal instrumental delivery n=2. Missing values: 2n=4, ³n=23. 
 
 
The rate of maternal intrapartum infection was 6% (Table 13). Two cases 
(0.5%) of blood culture positive maternal sepsis occurred. Postpartum 
infection rate was 4%, the most common postpartum infection being 
endometritis (2%). The overall rate of neonatal infections was 9%, and 3% 
with a diagnosis of clinical sepsis (Table 13). 
RISK FACTORS FOR CESAREAN DELIVERY 
 
The univariate and multivariate analyses of risk factors for CS after IOL are 
presented in Table 14. Advanced maternal age ≥ 37 years (OR 1.9), obesity 
(OR 1.8), gestational diabetes (OR 1.9), and Bishop score ≤ 3 (OR 1.6) were 
associated with an increased risk of CS following IOL in nulliparous women 
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(Table 14). After multivariate logistic regression analysis, the factors 
associated with an increased risk of CS were need for oxytocin induction (OR 
2.9) and need for early epidural analgesia (OR 9.9) (Table 14). 
 
Table 14. Univariate and multivariate analyses of risk factors for CS after IOL by FC in 







(n=169) Univariate analysis Multivariate analysis 
 % (n) % (n) OR (CI 95%) p-value OR (CI 95%) p-value 
Maternal age ≥37 
(years) 10 (43) 14 (23) 1.9 (1.0−3.6) 0.04 0.6 (0.3−1.3) 0.22 
IVF ¹ 4 (19) 5 (9) 1.4 (0.6−3.6) 0.45 0.7 (0.2−2.1) 0.52 
Smoking  14 (61) 14 (24) 1.0 (0.6−1.8) 0.97 1.0 (0.5−2.0) 0.95 
BMI ≥30²  15 (64) 20 (33) 1.8 (1.1−3.1) 0.03 0.7 (0.4−1.3) 0.23 
Gestational 
diabetes 19 (81) 25 (42) 1.9 (1.2−3.1) 0.01 0.6 (0.3−1.1) 0.12 
Bishop score ≤3 at 
IOL start¹ 48 (206) 55 (93) 1.6 (1.1−2.4) 0.02 1.3 (0.8−2.1) 0.21 
Cervical effacement 
>2 cm at amniotomy  7 (32) 9 (16) 1.5 (0.6−2.1) 0.85 1.1 (0.5−2.5) 0.84 
Cervical dilation ≤3 cm 
at amniotomy  4 (19) 78 (132) 1.6 (0.8−3.4) 0.19 0.8 (0.4−1.6) 0.52 
Amniotomy >12 h 
after balloon 
expulsion 
11 (47) 11 (19) 0.9 (0.5−1.7) 0.79 1.1 (0.5−2.1) 0.87 
Need for oxytocin 
induction 44 (188) 61 (103) 3.3 (2.2−4.9) <0.001 2.9 (1.9−4.5) <0.001 
Early epidural 
analgesia  3 (15) 9 (15) 11.2 (2.5−50.5) 0.002 9.9 (2.1−47.5 0.004 
¹Missing values 2. ²Missing values 4. 
RISK FACTORS FOR MATERNAL INFECTIOUS MORBIDITY 
 
Maternal infections were not associated with FC retention time, early or 
delayed timing of amniotomy, or early or delayed timing of oxytocin 
induction. The duration of labor was longer in cases of intrapartum infection 
compared to women with no infection (15[7–25] h vs. 12[0.6–35] h; 
p=0.015). Maternal infections were more common in women who delivered 
by CS compared to women who delivered vaginally (intrapartum infection 
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OR 7.7, 95% CI 2.9–20.8; p<0.001, and postpartum infection OR 3.9, 95% CI 
1.4–11.4; p=0.007). 
 
In univariate analysis, gestational diabetes was associated with an increased 
risk of intrapartum infection (OR 3.3) (Figure 20), and this association 
remained significant after multivariate regression analysis (OR 4.3, 95% CI 




Figure 20. Univariate analysis of ORs for maternal intrapartum infection in nulliparous 
women undergoing IOL by FC (II). 
 
RISK FACTORS FOR NEONATAL INFECTIOUS MORBIDITY 
 
Neonatal infections occurred more often following CS than vaginal delivery 
(OR 5.0, 95% CI 2.4–10.6; p<0.001 for clinical sepsis and OR 18.2, 95% CI 
2.3–142.6; p=0.001 for suspected sepsis). More cases of clinical neonatal 
infection were observed in women who received oxytocin administration > 12 
hours after amniotomy compared to ≤ 12 hours after amniotomy (16% vs. 
7%; p=0.04), but this association did not remain significant after logistic 
regression analysis. 
 
Maternal age ≥ 37 years (OR 4.9), gestational diabetes (OR 4.6), and early 
epidural analgesia (OR 6.0) were associated with an increased risk of 
neonatal clinical infection (Figure 21). After multivariate regression analysis, 
only the association with early epidural analgesia remained significant (OR 




Figure 21. Univariate analysis of ORs for neonatal infection following IOL by FC in 
nulliparous women (II). 
 
 
COMPARISON OF FOLEY CATHETER AND ORAL 
MISOPROSTOL FOR INDUCTION OF LABOR IN WOMEN 
WITH PREMATURE RUPTURE OF MEMBRANES AT 
TERM (III) 
 
A total of 47% (n=89) of the women underwent IOL by FC and 53% (n=99) 
by misoprostol after PROM at term. Table 15 shows the clinical 
characteristics of the study population. 
Table 15. Clinical characteristics of the women undergoing IOL by FC or oral misoprostol 
after PROM at term (n=188) (III) 
 
 FC (n=89) Misoprostol (n=99) p-value 
Maternal age ≥35 years 21 (19) 19 (19) 0.41 
Nulliparous 74 (66) 78 (77) 0.53 
BMI ≥30 15 (13) 18 (18) 0.51 
Bishop score ≤3 at the start of IOL 25 (22) 33 (33) 0.20 
Gestational age 39.9 [1.2] 39.8 [1.2] 0.71 
Duration of PROM 29.0 [18–42] 30.0 [18–168] 0.04 
GBS-positive 20 (18) 19 (19) 0.89 





FC was retained for a median (range) time of 6(0.6–18) h. Of the women 
undergoing IOL by misoprostol, 49% (n=49) needed one dose, 30% (n=30) 
needed two doses, and 20% (n=20) needed three or more doses of 
misoprostol. Oxytocin was more often needed for inducing contractions 
following the use of FC compared to use of misoprostol (42% vs. 18%; 
p<0.001). However, oxytocin augmentation during labor was as frequent in 
both groups (88% vs. 86%; p=0.72). The use of opioids (27% vs. 39%; 
p=0.07) and epidural or spinal analgesia (83 vs. 85; p=0.76) was not 
significantly different between the induction methods. 
DELIVERY OUTCOMES 
 
The delivery outcomes are presented in Table 16. The CS rates were not 
significantly different between the groups (24% vs. 18%; p=0.36). The rates 
of maternal intrapartum infections, postpartum infections, and neonatal 
infections were similar (Table 16). All women were screened for GBS, and 
20% were positive. One case of intrapartum infection following misoprostol 
induction occurred in a GBS-positive woman, while all other maternal and 
neonatal infections occurred in GBS-negative women. There were no cases of 
laparotomy or hysterectomy. The induction to delivery interval was similar in 
both groups (22 h in FC group vs. 24 h in misoprostol group; p=0.31). 
Table 16. Delivery outcomes of the women undergoing IOL by FC (n=89) and misoprostol 
(n=99) (III) 
 
 FC (n=89) Misoprostol (n=99) p-value 
CS 24 (21) 18 (18) 0.36 
Failure to progress 17 (15) 8 (8) 0.07 
Fetal distress 6 (5) 10 (10) 0.26 
Intrapartum infection 1 (1) 0  0.47 
Postpartum hemorrhage ≥1000 ml 13 (12) 13 (13) 0.89 
Fetal tachycardia 7 (6) 9 (9) 0.55 
Hyperstimulation 2 (2) 4 (4) 0.69 
Intrapartum infection 2 (2) 2 (2) − 
Postpartum endometritis 1 (1) 2 (2) − 
Apgar score 1 min <7¹ 2 (2) 2 (2) 1.00 
Apgar score 5 min <7¹ −  −  − 
Umbilical artery pH <7.05² 1 (1) 2 (2) 0.50 
Umbilical artery BE ≤−12.0² −  3 (3) 0.25 
Neonatal infection 1 (1) 5 (5) 0.22 
Admission to neonatal ward 8 (7) 9 (9) 0.76 
Data presented as % (n).¹Missing values 1. ²Missing values 7. 
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OUTPATIENT COMPARED TO INPATIENT SETTING OF 
LABOR INDUCTION BY FOLEY CATHETER (IV) 
 
Table 17 presents the characteristics of the study IV population (n=485). The 
most common IOL indication for both groups was prolonged or post-term 
pregnancy (89% [n=182] of outpatients and 90% [n=253] of inpatients), but 
more post-term women ended up in the inpatient group (16% vs. 34%; 
p<0.001, Table 17). 
 
Table 17. Characteristics of the inpatients and outpatients undergoing IOL by FC (n=485) 
(IV) 
 
 Outpatients (n=204) Inpatients (n=281) p-value 
Maternal age ≥35 years 22 (44) 21 (58) 0.44 
Nulliparous 64 (131) 64 (181) 0.96 
BMI ≥30 16 (32) 15 (42) 0.82 
Bishop score ≤3 at the start of IOL 43 (88) 37 (104) 0.09 
Gestational age 41.7 [0.9] 41.7 [0.9] 0.97 
Post-term pregnancy (≥42+0) 16 (32) 34 (95) <0.001 
History of previous CS 15 (31) 16 (46) 0.73 
Data presented as % (n) or mean (SD). SD = standard deviation. 
 
The reasons for contacting the delivery unit during outpatient cervical 
ripening are shown in Table 18, expulsion of the balloon (59%) being the 
most common reason. The return rate to hospital for reasons other than 
expulsion of the balloon, onset of labor, or reaching 24 hours of cervical 
ripening was 7% (Table 18). The median (range) retention time of FC was 
longer in outpatients than in inpatients (10[0.1–27] h vs. 7[0.1–26] h; 
p<0.001). FC expulsion occurred during nighttime in 13% (n=36) of the 
inpatients and 23% (n=47) of the outpatients, whose amniotomy was 
postponed for 8–12 hours to the following morning. 
 
Table 18. Reason for contacting the delivery unit during outpatient cervical ripening (n=204) 
 
Reason for contacting % (n) 
Balloon expulsion 59 (121) 
Reaching 24 hours of cervical ripening 25 (50) 
Onset of labor 9 (18) 
Rupture of membranes 2 (4) 
Other1 5 (11) 
1Suspected rupture of membranes n=3, vaginal bleeding n=3, difficulty urinating n=2, decreased fetal 





The maternal and neonatal outcomes are summarized in Table 19. No cases 
of home delivery, placental abruption, intrauterine fetal death, or severe pain 
occurred in inpatient or outpatient IOL by FC. The rates of CS were not 
significantly different between outpatients and inpatients (32% vs. 32%; 
p=0.82). Duration of labor was similar between the inpatients and 
outpatients, but the median (range) induction to delivery interval was longer 
in outpatients than in inpatients (31[4−82] h vs. 25[3−71] h; p<0.001). The 
rates of maternal and neonatal infections, postpartum hemorrhage, or 
neonatal care admission were not significantly different between the groups 
(Table 19). 
Table 19. Maternal and neonatal outcomes of outpatients and inpatients undergoing IOL by 
FC (IV) 
 













CS 38 (44) 39 (64) 0.87 21 (15) 20 (19) 0.85 
PPH ≥1000 ml         
        Vaginal delivery 7 (8) 9 (15) 0.47 10 (7) 6 (6) 0.38 
        CS 15 (17) 13 (22) 0.65 4 (3) 5 (5) 1.00 
Intrapartum infection 7 (8) 6 (9) 0.62 6 (4) 2 (2) 0.40 
Postpartum infection 6 (7) 2 (4) 0.21 3 (2) 2 (2) 1.00 
Apgar score 1 min <7 10 (12) 10 (16) 0.87 10 (7) 5 (5) 0.26 
Apgar score 5 min <7 4 (5) 4 (7) 0.98 4 (3) 3 (3) 0.71 
Umbilical artery pH 
<7.05 3 (3) 1 (2) 0.65 4 (3) 3 (3) 0.74 
Umbilical artery BE 
≤−12.0 3 (3) 2 (4) 1.00 3 (2) 2 (2) 1.00 
Neonatal infection 10 (12) 8 (13) 0.48 −  5 (5) 0.07 
Admission to NICU 2 (2) 3 (5) 0.49 3 (2) −  0.25 
Admission to 
neonatal ward 16 (18) 12 (19) 0.33 6 (4) 9 (8) 0.50 
Data presented as % (n). PPH =Postpartum hemorrhage 
MATERNAL SATISFACTION ON OUTPATIENT PROCEDURE 
 
Of the 112 women (55%) who returned the Likert scale questionnaire after 
delivery, 85% were satisfied with outpatient induction (very positive 71%, 
positive 15%, no opinion 10%, negative 0%, very negative 5%), and 91% were 
satisfied with the contact information and counseling provided (very positive 
74%, positive 16%, no opinion 2%, negative 2%, very negative 5%). 
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CERVICAL INSULIN-LIKE GROWTH FACTOR BINDING 
PROTEIN-1 AND MATRIX METALLOPROTEINASES IN 
LABOR INDUCTION BY FOLEY CATHETER (V) 
CLINICAL CHARACTERISTICS AND DELIVERY OUTCOMES 
 
The characteristics and delivery outcomes of the study V population (n=34) 
are summarized in Table 20. The median (range) gestational age was 41.9 
(40.0–42.1) weeks, and 47% of the women were post-term (Table 20). Half of 
the women had Bishop score ≤ 3 at the insertion of FC. 
 
Table 20. Characteristics and delivery outcomes of study V population (n=34) 
 
Clinical characteristic/delivery outcome % (n) 
Maternal age 31 [4] 
BMI ≥30  15 (5) 
Gestational diabetes 26 (9) 
Bishop score ≤3 at start of IOL 50 (17) 
Post-term pregnancy (≥42+0) 47 (16) 
Vaginal delivery 56 (19) 
CS  44 (15) 
Fetal distress 6 (2) 
Labor arrest 18 (6) 
Failed induction 15 (5) 
Other¹ 6 (2) 
Postpartum hemorrhage ≥1000 ml 24 (8) 
Data presented as % (n) or mean [SD]. SD = standard deviation. 
¹Umbilical cord prolapse n=1, epileptic seizure. 
CONCENTRATIONS OF CERVICAL BIOMARKERS 
 
The concentrations of IGFBP-1 and phIGFBP-1 increased, while the 
concentrations of MMP-8 and MMP-9 decreased during cervical ripening by 
FC in nulliparous women (Figure 22). MMP-2 concentration remained low 
with no significant change during FC retention. The concentration of TIMP-1 
did not significantly change, whereas the TIMP-2 concentration decreased 
during FC induced cervical ripening (Figure 22). 
 
The highest increase of IGFBP-1 and phIGFBP-1 concentrations was 
observed in women who started spontaneous contractions. At start of IOL, 
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the median MMP-8 concentration was higher in women with Bishop score ≤ 
3 compared to women with Bishop score > 3 (593 μg/L vs. 408 μg/L; 
p=0.02). Also, the MMP-8 concentrations decreased more in women with 
Bishop score ≤ 3 compared to women with Bishop score > 3 (443 μg/L vs. 
209 μg/L; p=0.01). The concentrations of these selected cervical biomarkers 
were not significantly different between the women who delivered vaginally 




Biomarker FC insertion FC expulsion p-value 
phIGFBP-1 6 (0.3–976) 76 (3–1530) 0.008 
IGFBP-1 2 (0.1–261) 24 (1–718) 0.001 
MMP-2 9 (1–39) 6 (2–30) 0.45 
MMP-8 446 (28–1998) 230 (23−661) <0.001 
MMP-9 433 (11–3019) 178 (14–667) <0.001 
TIMP-1 16 (1–162) 32 (7–172) 0.88 
TIMP-2 26 (1–111) 19 (1–539) 0.002 
Figure 22. Concentrations (median; range) of cervical biomarkers in nulliparous women at 
FC insertion and expulsion. IGFBP-1 and pHIGFBP-1 increased, whereas MMP-8, MMP-9, 












MANAGEMENT OF LABOR INDUCTION BY FOLEY 
CATHETER 
Similar to our study IV, several protocols suggest that outpatient cervical 
ripening is safe and feasible for women with uncomplicated pregnancies (24, 
220, 309-311). Outpatient cervical ripening shortens the hospitalization 
period, optimizes the delivery unit capacity, and may decrease health care 
costs (26, 36). Antenatal care episodes in Helsinki University Hospital 
(Maternity hospital) decreased by 16% after introducing the outpatient 
protocol (IV), although we did not assess the health care costs during study 
IV. One of the key questions is the readmission rate of the outpatients. In our 
study IV, the return rate to hospital for reasons other than labor, rupture of 
membranes, balloon expulsion, or reaching 24 hours of home cervical 
ripening, was 7%, as also reported previously (24). We believe this low was 
due to the detailed counseling and 24-hour contact information provided 
during the study IV. 
 
Our results suggest that FC can safely remain in the cervical canal for 24 
hours in women with intact amniotic membranes (I–II, IV–V), and at least 8 
hours with antibiotic prophylaxis in women with PROM (III). In previous 
studies, FC retention time of 12–24 hours is frequently described (199, 312), 
although a recent Dutch study used a maximum of 96 hours with FC 
replacement every 24–48 hours, with no increase in the rates of maternal 
and neonatal infectious morbidity (22). In our study II, the duration of FC 
remaining in the cervical canal had no association with infectious morbidity. 
In contrast, a previous study reported an increase in cervical pathogenic 
microbes, such as GBS, Candida albicans and Candida glabrata, and 
Gardnerella vaginalis during FC retention (101). 
 
Our study suggests that early or delayed amniotomy following balloon 
expulsion had no association with the mode of delivery (II). This is in line 
with a previous study reporting no difference in CS rate following early 
amniotomy at < 4 cm of cervical dilation in nulliparous women (228). 
However, a recent retrospective cohort study on 546 nulliparous women 
concluded that amniotomy within one hour of FC expulsion, compared to 
delay of 4 hours or more, was associated with shorter induction to delivery 
interval and a higher frequency of vaginal deliveries within 24 hours (230). 
 
The oxytocin administration rate during labor is approximately 47% in 
Finland, while in Helsinki University Hospital it is 60% (4). In our study, the 
rate of oxytocin usage was approximately 85% (I–V). The rate of oxytocin 
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usage was high both in induced and spontaneous labors (I). Unfortunately, 
we did not differentiate between oxytocin use in the first and the second 
stages of labor. Oxytocin was more often needed for labor induction 
following the use of FC compared to misoprostol (III), as also noted in 
previous studies (17, 18). A recent study suggests that discontinuing oxytocin 
during the active phase of labor may improve delivery outcomes but increase 
the duration of the active phase of labor by an average of 40 minutes (240). 
In our study, oxytocin administration was determined by the managing 
midwife and obstetrician without a strict protocol, and some women may 
have been unnecessarily treated with continuous oxytocin during the active 
phase of labor. High rate of oxytocin use and discontinuous administration 
may also partly explain some of the CS due to fetal distress during our 
studies I–V. 
 




The highest CS rates in our study were observed in nulliparous women with 
prolonged and post-term pregnancies (I–II, V), which is in line with previous 
reports (262, 263). In our study I, the rate of CS in induced labor at or 
beyond 41+5 weeks was sixfold compared to spontaneous labor. In contrast, 
IOL in multiparous women more often resulted in vaginal delivery (I, IV). 
Previously IOL, regardless of the method, has been associated with a three- 
to eightfold increase in CS rate compared to spontaneous labor at or beyond 
term (261), but more recent studies have demonstrated a reduction in CS 
following IOL at term compared to expectant management (27-31). In our 
study I, the groups were different with a selection bias of more nulliparous 
and post-term women ending up in the induction group. Additionally, we 
focused on a narrow time frame between 41+5 and 42+1 gestational weeks. 
Thus, our results (I) are inapplicable for further conclusions on timing of IOL 
with regard to CS rates. 
 
Our results show no difference in the CS rates between FC and misoprostol 
induced labors (III), as also previously demonstrated (19, 20, 173). 
Interestingly, a lower CS rate of 4.5% with no increase in infections has been 
observed with an expectant management policy of 48 hours after PROM (97). 
In our study, the overall rate of CS was lower in IOL following PROM (III) 
compared to other indications (24% vs. 33%; p<0.001) (III, IV−V). In our 
study, PROM appears to have a positive impact on the progress of induced 
labor in women with an unfavorable cervix. It may be contemplated that 
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perhaps PROM occurred as a result of a biochemical activation process, 
which led to the process of cervical ripening and rupture of membranes, thus 
resulting also in more successful labor induction in these women. The rate of 
CS was not significantly different between inpatients and outpatients (IV), 
which is in accordance with previous studies (24, 26, 288, 310). 
MATERNAL INFECTIOUS MORBIDITY 
 
The median (range) maternal infection rates of intrapartum infections 
5(2−6)% and postpartum infections 3(1−4)% in our studies I−V are 
consistent with the previously shown 7% rate of chorionamnionitis, and 3.5% 
rate of postpartum endometritis following labor induction (16). The rate of 
maternal infections is higher in induced compared to spontaneous labor 
(0.2−1.5%) (313). An older systematic review has linked FC with an increased 
risk of infections (174), but in more recent studies FC has not been associated 
with increased infectious morbidity compared to PGs (16, 18, 19, 165, 173). 
The rates of maternal infections were not different between the groups of FC 
and misoprostol (III), as also previously reported (16). Furthermore, 
outpatients and inpatients undergoing IOL by FC had similar rates of 
infectious maternal morbidity (IV), which is in accordance with previous 
studies (24, 26, 310). 
 
The use of FC in women with ruptured amniotic membranes has raised 
concerns over infectious morbidity. In our study III, however, the maternal 
infection rates were the lowest following IOL by FC in cases of term PROM. 
On the other hand, prophylactic antibiotics were used for all women in our 
study III, which may have led to a reduced rate of infections. Another factor 
related to low infectious morbidity may have been the shorter duration of 
induced labor following PROM compared to IOL in non-PROM cases (22 h 
vs. 30 h) (II, III). Similar reassuring results on IOL by FC after PROM at 
term have been previously reported by a small Swedish pilot study (n=18) 
and a retrospective cohort study (n=122) (314, 315). 
 
The highest rate of maternal infections was seen in nulliparous women (II). 
Unfortunately, the placental histopathological diagnosis of 
chorionamnionitis was not available in all cases. Duration of labor, duration 
of ruptured membranes, use of internal fetal monitoring, presence of 
meconium, number of vaginal examinations, use of prophylactic antibiotics, 
and GBS screening protocols are factors associated with rates of infectious 
morbidity (313). In our study, gestational diabetes was associated with 
maternal infections (II). Similar results were reported by a Danish study 
(n=2492), in which gestational and pregestational type 2 diabetes were 
associated with an increased risk of postpartum infections (316). Maternal 
infections were also associated with prolonged labor, CS, and nulliparity 
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(III), as also noted previously (317). Increased risk of chorionamnionitis has 
been demonstrated in nulliparous women remaining in the latent phase for 
more than 12 hours (284). 
NEONATAL INFECTIOUS MORBIDITY 
 
In our studies I−IV, the median (range) rate of neonatal clinical sepsis 
following IOL was 1.8(1–3) %, which parallels the results of previous studies 
(16). No blood culture positive neonatal sepsis cases occurred during our 
studies I−V, whereas a sepsis incidence of approximately 1 per 1000 live 
births has been previously reported (318). The rates of neonatal infections 
are known to vary by geographic region, resource use, and management 
practices, such as GBS screening or use of prophylactic antibiotics. 
 
The neonatal infection rates were similar in the groups of FC and misoprostol 
IOL (III), as also reported by a recent review and meta-analysis (16). 
Consistent with previous studies, outpatient cervical ripening by FC did not 
result in increased neonatal infectious morbidity compared to inpatient 
cervical ripening (IV) (24, 26, 310). Furthermore, the neonatal infection rate 
was low (1%) in women undergoing IOL by FC following term PROM ≥ 18 
hours. Our results add to the limited data on the use of FC in women with 
term PROM, and suggest that with regards to neonatal infectious morbidity, 
FC seems a safe and feasible method of IOL. 
 
In nulliparous women, the incidence of neonatal infections was higher in 
induced compared to spontaneous labor (I). However, the rates of clinical 
neonatal sepsis were similar between these groups, whereas the rate of 
suspected neonatal infections was higher in induced labors (I). We speculate 
that the use of FC, a relatively new method at the time of the study, may have 
resulted in a lower threshold for starting antibiotics in cases of prolonged 
induction to delivery intervals, and to more neonates being admitted for 
observation. Unfortunately, further comparisons between spontaneous and 
induced labors are limited, since the rates of suspected neonatal infections 
are not included in most studies, and data on the rates of blood culture 
negative neonatal infections following spontaneous labor are not available. 
 
The majority of neonates diagnosed with infection in our studies I and II 
were delivered by CS. Neonatal infection may have occurred in the absence of 
maternal infection, and maternal infection did not always lead to neonatal 
infection, although maternal chorionamnionitis may increase the risk of 
neonatal infection by 1–4% (319). Early epidural analgesia was associated 
with an increased risk of neonatal infection in our study II, but this may 
rather be related to prolonged latent phase of induced labor, which is a 
known risk factor for infectious morbidity. 
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OTHER DELIVERY OUTCOMES 
 
Maternal and neonatal outcomes were similar between induced or 
spontaneous labor in prolonged or post-term pregnancy (I), IOL by FC or 
misoprostol following PROM at term (III), and between inpatients and 
outpatients (IV). IOL itself has been associated with increased admissions to 
neonatal unit (93, 284), but this was not seen in our studies I–V. Moreover, 
admissions to NICU and to neonatal unit were similar between induced and 
spontaneous labor, between FC and misoprostol (III), and between 
outpatients and inpatients (IV), as also shown in previous studies (18, 310). 
In accordance with previous studies, most women were satisfied with 
outpatient IOL, and found contacting the delivery unit feasible (220, 288, 
289). 
 
A retrospective cohort study by Mackeen et al. reported shorter induction to 
delivery interval (12.3 h vs. 22.6 h; p<0.01) in women undergoing IOL by FC 
compared to misoprostol following PROM at term (314). In our study III, no 
difference in the induction to delivery interval was found between these two 
methods. The induction to delivery interval was longer in outpatients than in 
inpatients (IV), as also previously noted (24). This may be explained by the 
fact that amniotomy was in outpatients often delayed to the next morning in 
case of FC expulsion at night. However, the durations of the first and second 
stages of labor were similar in outpatients and inpatients (IV). 
 
FACTORS ASSOCIATED WITH SUCCESS OF LABOR 
INDUCTION BY FOLEY CATHETER 
 
Advanced maternal age, obesity, gestational diabetes, and an unfavorable 
cervix were risk factors for CS in our study II, as also reported by several 
previous studies (86, 87, 261, 270). We also noticed that the cervix further 
ripened from unfavorable to favorable only in every tenth woman during 
expectant management from 41+5 to 42+1 gestational weeks (I). We used the 
Bishop score to assess the degree of cervical ripeness, with a score ≥ 6 being a 
marker for a favorable cervix. Since the Bishop score was originally derived 
from multiparous women (48), a more preferable concept for favorable 
cervix in nulliparous women could be Bishop score ≥ 8 (5). It may also be 
speculated that despite an improved Bishop score following FC expulsion, the 
cervical ripening process, such as remodeling of collagen, had not yet 
commenced (320). Furthermore, higher cervical collagen concentrations 
have been reported in women with failure to progress compared to women 
with normal progress of labor (320). It has been suggested that initiating 
cervical ripening gradually and earlier in nulliparous women with 
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unfavorable cervices may improve delivery outcomes, although no studies 
have yet addressed the issue. 
 
We found that the need for oxytocin induction and early epidural analgesia 
were associated with an increased risk of CS in nulliparous women (II), as 
also noted in a previous study (263). However, this may be explained by the 
fact that factors associated with early request for epidural analgesia, such as 
IOL, oxytocin use, and nulliparity, are all also linked to increased risk of CS 
(321). 
 
The most common indications for CS following IOL by FC were failed 
induction and labor arrest (I−V), as also previously reported (12, 173, 199). 
Previous studies conclude that before considering an induction failed, at least 
12 hours of latent phase in the setting of ruptured membranes and oxytocin 
administration should be allowed for nulliparous women, and 15 hours for 
multiparous women (282, 284, 286). Furthermore, transition to active labor 
occurs only at 6 cm of cervical dilation following IOL by FC (285). In our 
studies I–V, oxytocin was administered predominantly for 6−12 hours, the 
timing of oxytocin administration altered, and the definitions for failed 
induction and labor arrest varied. Therefore, in some cases failed induction 
may have been diagnosed too early. We speculate that some CSs performed 
due to suspected labor arrest may have been partly due to physician related 
factors, such as medical concerns or false interpretation on progress of 
induced labor, and patient related factors, such as maternal exhaustion and 
preference for CS. Also, some CSs might have been avoided if there had been 
a standardized management protocol for labor induction. 
 
Post-term pregnancy is associated with increased rates of perinatal 
complications and operative delivery (28, 32, 33), as also seen in our studies 
I−II, IV−V. A recent retrospective cohort study comparing expectant 
management and elective IOL between 38 and 42 gestational weeks 
suggested that the curve for CS risk was U-shaped with the nadir at 39 
gestational weeks (322). In Finland, the first fetal monitoring in 
uncomplicated pregnancy is scheduled at 41+5 gestational weeks, and IOL is 
carried out between 41+5 and 42+1 gestational weeks. Routine IOL at 41 
gestational weeks would increase the rates of labor induction and use of 
health care resources. On the other hand, earlier IOL may decrease cesarean 
deliveries, perinatal complications, and episodes of neonatal care, thus 




CERVICAL IGFBP-1 AND MMPS IN FOLEY CATHETER 
INDUCTION (V) 
 
Our results suggest that IGFBP-1, phIGFBP-1, MMP-8, MMP-9, and TIMP-2 
are involved in the process of cervical ripening. However, the changes in 
these cervical biomarker concentrations showed no correlation with CS due 
to labor arrest or failed induction, thus appearing not suitable for predicting 
the outcome of labor induction in clinical use. The study investigated only 
nulliparous women, since the concentrations of phIGFBP-1 and MMP-8 have 
been shown to differ between nulliparous and multiparous women (323, 
324). 
 
In our study, the IGFBP-1 concentrations increased during cervical ripening 
without predicting the induction to delivery interval, as also seen previously 
(64). The presence of cervical phIGFBP-1 may predict successful vaginal 
delivery (65), but this was not observed in our study V. However, IGFBP-1 
and phIGFBP-1 concentrations increased more during FC induced cervical 
ripening in women who started spontaneous contractions, as also previously 
demonstrated (65). 
 
In contrast to a previous study by Lim et al., which showed an increasing 
trend (69), the MMP-8 and MMP-9 concentrations decreased during FC 
induced cervical ripening in our study. In addition, the starting levels and the 
decrease were also greater in women with less ripe cervices. Our results 
suggest that the decrease in MMP-8 and MMP-9 concentrations may reflect 
reduced defensive potential during cervical ripening (325). In our study, the 
TIMP-2 concentrations also decreased, which may reflect interaction with 
MMPs, and the homeostatic regulation of extracellular matrix remodeling by 
TIMPs (67). Furthermore, in the study by Lim and colleagues, the study 
design and sampling technique differed from ours, and the correlations 
between biomarkers and IOL outcomes were not analyzed (69). 
 
STRENGTHS AND WEAKNESSES OF THE STUDY 
 
The strengths of the study include a well-defined study population of a 
tertiary care unit with approximately 14 000 deliveries annually, uniform 
dating of pregnancy by first trimester ultrasound, systematically recorded 
hospital- and registry-based data, and extensive experience of the use of FC. 
To our best knowledge, study III is the largest RCT on use of FC after PROM 
at term. In study V, the sampling technique and management of cervical 




The major limitation of studies I and II is the retrospective design. The study 
design (I) may have led to a selection bias of more post-term and nulliparous 
women ending up in the IOL group. Another obvious weakness is the lack of 
power analyses in determining the sample sizes (I, II), although this can be 
explained by the fact that we chose a cohort of one year. Also, the approach of 
focusing on the narrow time frame between 41+5 and 42+1 weeks may to 
some extent offset the lack of power in study I. In study III, the main 
limitation was the relatively small number of patients enrolled. Furthermore, 
unfortunately we did not assess patient satisfaction (III). We also 
acknowledge the lack of randomization on the setting of IOL (IV), and regret 
not assessing the economic impact of the outpatient procedure (IV). 
However, this was a pilot study emphasizing feasibility, and also emphasizing 
maternal preference on the setting of IOL (IV). The main limitation of the 
study V was the small sample size. Also, there may have been inter-individual 
variation in vaginal bacterial flora and cervical mucus cellularity reflected in 
the biomarker concentrations (V). We are also aware that characteristics and 
practice patterns demonstrated in the studies may not be applicable to other 
settings. Also, the management of labor induction may have been influenced 
by lack of standardized protocol, as well as delivery unit capacity, human 




The rates of labor induction are anticipated to rise as the methods of fetal 
monitoring improve, and vaginal delivery, including the role of vaginal 
microbiome during labor, will be promoted over non-medically indicated 
cesarean deliveries. After discovering the exact mechanism of labor onset, 
related to the telomere loss and cell-free fetal DNA theory, prediction of 
successful labor induction will hopefully become common practice. The 
concentrations of cell-free fetal DNA, cervical collagen, myometrial oxytocin 
receptors, and biochemical mediators, measured from maternal serum, 
cervical tissue, and amniotic fluid, might in the future help to analyze the 
optimal timing of IOL and delivery. Additionally, several bedside screening 
tests for activation of the trigger for parturition, and success of labor 
induction, may be developed. Labor induction may become digitalized, as 
small cervical, myometrial and amniotic electrodes connected to a wireless 
transmitter could be used to follow the progress of labor induction and labor, 
as well as to predict the delivery outcome. Instead of comparing the use of 
PGs and balloon catheters, combined use might be the method of choice in 
the future. The pharmaceutical industries may release new balloon catheters 
secreting continuous or pulsed low dose PGs. As the new methods evolve, the 
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obstetricians can regulate PG dosage and balloon pressure from a distance, 
depending on the information a sensor attached to the cervical ripening 
device sends to the patient’s medical record. Furthermore, fetal 
cardiotocography may be remotely simultaneously monitored in a digital 
fashion. 
 
However, as we wait for the knowledge and techniques to evolve, the high 
rate of CS in nulliparous women today is of concern and requires further 
assessment. One may speculate that in the absence of the underlying 
biochemical trigger leading to cervical ripening and onset of labor, IOL fails 
to result in successful vaginal delivery regardless of the management 
practice. Further studies on suitable biomarkers for bedside screening on the 
success of IOL are needed. On the other hand, optimal timing of IOL may 
also decrease the rates of CS, perinatal complications, and health care costs. 
Use of FC after PROM remains one of the questions to be investigated 
further. We were also encouraged by the pilot study on outpatient IOL, and a 
randomized trial on the setting of labor induction including a cost analysis 































1. Labor induction with FC in prolonged or post-term pregnancy 
does not increase maternal or neonatal morbidity compared to 
spontaneous onset of labor, but is associated with an increased 
rate of cesarean delivery in nulliparous women. 
 
2. IOL by FC is associated with a high rate of CS in term 
nulliparous women. Advanced maternal age ≥ 37, obesity, 
gestational diabetes, Bishop score ≤ 3, need for oxytocin 
induction, and request for early epidural analgesia are associated 
with an increased risk of cesarean delivery. Gestational diabetes 
and early epidural analgesia are associated with infectious 
morbidity in these pregnancies. 
 
3. FC and oral misoprostol can both be used for IOL in women with 
term PROM with no difference in the rates of cesarean delivery, 
or maternal or neonatal infectious morbidity when prophylactic 
antibiotics are used. 
 
4. IOL by FC appears safe and feasible as an outpatient procedure, 
and results in no difference in the rate of CS, or maternal and 
neonatal infectious morbidity compared to inpatients. Most 
women are satisfied with outpatient IOL. 
 
5. The concentrations of cervical biomarkers IGFBP-1 and 
phIGFBP-1 increase, whereas MMP-8, MMP-9, and TIMP-2 
concentrations decrease during FC induced cervical ripening in 
nulliparous women. However, these changes do not predict the 
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